<Summary id="CDR0000062958" LegacyPDQID="916"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Non-Hodgkin lymphoma (NHL) options include chemotherapy, radiation, targeted therapy, plasmapheresis, surveillance, stem cell transplant, and surgery. Learn more about types of NHL and treatments in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq">Non-Hodgkin Lymphoma (PDQ®): Treatment</SummaryURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000042800">adult non-Hodgkin lymphoma</TermRef></MainTopics><SummaryAbstract><Para id="_450">This PDQ cancer information summary has current information about the treatment of non-Hodgkin lymphoma. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_451">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Adult Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>adult non-Hodgkin lymphoma</SummaryKeyWord><SummaryKeyWord>anaplastic large cell lymphoma</SummaryKeyWord><SummaryKeyWord>Burkitt lymphoma</SummaryKeyWord><SummaryKeyWord>diffuse large b-cell lymphoma</SummaryKeyWord><SummaryKeyWord>follicular large cell lymphoma</SummaryKeyWord><SummaryKeyWord>follicular lymphoma</SummaryKeyWord><SummaryKeyWord>lymphoblastic lymphoma</SummaryKeyWord><SummaryKeyWord>lymphoplasmacytic lymphoma</SummaryKeyWord><SummaryKeyWord>marginal zone lymphoma</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Non-Hodgkin Lymphoma Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Non-Hodgkin Lymphoma Treatment</AltTitle><SummarySection id="_129"><Title>General Information About Non-Hodgkin Lymphoma</Title><SummarySection id="_130"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_131">Non-Hodgkin lymphoma is a disease in which malignant
		  (cancer) cells form in the lymph system.</KeyPoint><Para id="_132"><GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">Non-Hodgkin lymphoma</GlossaryTermRef> is a type of 
		  <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> that forms in the <GlossaryTermRef href="CDR0000045764" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>. The lymph system is part of the <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef>. It helps protect the body from <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease.</Para><Para id="_475">The lymph system is made up of the following:</Para><ItemizedList id="_476" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046305" dictionary="Cancer.gov" audience="Patient">Lymph</GlossaryTermRef>: Colorless, watery <GlossaryTermRef href="CDR0000044669" dictionary="Cancer.gov" audience="Patient">fluid</GlossaryTermRef> that travels through the <GlossaryTermRef href="CDR0000269462" dictionary="Cancer.gov" audience="Patient">lymph vessels</GlossaryTermRef> and carries <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef>). There are three types of lymphocytes:<ItemizedList id="_477" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B lymphocytes</GlossaryTermRef> that make <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> to help fight infection. Also called B cells. Most types of non-Hodgkin lymphoma begin in B lymphocytes.</ListItem><ListItem><GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T lymphocytes</GlossaryTermRef> that help B lymphocytes make the antibodies that help fight infection. Also called T cells.</ListItem><ListItem><GlossaryTermRef href="CDR0000044062" dictionary="Cancer.gov" audience="Patient">Natural killer cells</GlossaryTermRef> that attack cancer <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045941" dictionary="Cancer.gov" audience="Patient">viruses</GlossaryTermRef>. Also called NK cells.</ListItem></ItemizedList></ListItem><ListItem>Lymph vessels: A network of thin tubes that collect lymph from different parts of the body and return it to the bloodstream.</ListItem><ListItem><GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">Lymph nodes</GlossaryTermRef>: Small, bean-shaped structures that filter lymph and store white blood cells that help fight infection and disease. Lymph nodes are found along a network of lymph vessels throughout the body. Groups of lymph nodes are found in the neck, underarm, <GlossaryTermRef href="CDR0000046288" dictionary="Cancer.gov" audience="Patient">mediastinum</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045070" dictionary="Cancer.gov" audience="Patient">abdomen</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046246" dictionary="Cancer.gov" audience="Patient">pelvis</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046375" dictionary="Cancer.gov" audience="Patient">groin</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">Spleen</GlossaryTermRef>: An <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organ</GlossaryTermRef> that makes lymphocytes, stores <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef> and lymphocytes, filters the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>, and destroys old blood cells. The spleen is on the left side of the abdomen near the <GlossaryTermRef href="CDR0000046604" dictionary="Cancer.gov" audience="Patient">stomach</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046616" dictionary="Cancer.gov" audience="Patient">Thymus</GlossaryTermRef>: An organ in which T lymphocytes mature and multiply. The thymus is in the chest behind the <GlossaryTermRef href="CDR0000549425" dictionary="Cancer.gov" audience="Patient">breastbone</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046618" dictionary="Cancer.gov" audience="Patient">Tonsils</GlossaryTermRef>: Two small masses of lymph <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef> at the back of the <GlossaryTermRef href="CDR0000439429" dictionary="Cancer.gov" audience="Patient">throat</GlossaryTermRef>. There is one tonsil on each side of the throat.</ListItem><ListItem><GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">Bone marrow</GlossaryTermRef>: The soft, spongy tissue in the center of certain bones, such as the hip bone and breastbone. White blood cells, red blood cells, and <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> are made in the bone marrow.</ListItem></ItemizedList><MediaLink ref="CDR0000533339" type="image/jpeg" alt="Lymphatic system; drawing shows the lymph vessels and lymph organs, including the lymph nodes, tonsils, thymus, spleen, and bone marrow. Also shown is the small intestine (one site of mucosal-associated lymphoid tissue). There are also two pullouts: one showing a close up of the inside structure of a lymph node and the attached artery, vein, and lymph vessels with arrows showing how the lymph (clear, watery fluid) moves into and out of the lymph node, and another showing a close up of bone marrow with blood cells." language="en" placement="image-center" id="_297"><Caption language="en">The lymph system is part of the body's immune system and is made up of tissues and organs that help protect the body from infection and disease. These include the tonsils, adenoids (not shown), thymus, spleen, bone marrow, lymph vessels, and lymph nodes. Lymph tissue is also found in many other parts of the body, including the small intestine. </Caption></MediaLink><Para id="_134">Lymph tissue is also found in other parts of the body such as the lining of the <GlossaryTermRef href="CDR0000046447" dictionary="Cancer.gov" audience="Patient">digestive tract</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045629" dictionary="Cancer.gov" audience="Patient">bronchus</GlossaryTermRef>, and skin. </Para><Para id="_502">There are two general types of <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphomas</GlossaryTermRef>: <GlossaryTermRef href="CDR0000270800" dictionary="Cancer.gov" audience="Patient">Hodgkin lymphoma</GlossaryTermRef> and non-Hodgkin lymphoma. This summary is about the treatment of non-Hodgkin lymphoma in adults, including during <GlossaryTermRef href="CDR0000666677" dictionary="Cancer.gov" audience="Patient">pregnancy</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_136"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData></SummarySection><SummarySection id="_376"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_377">Non-Hodgkin lymphoma can be indolent or aggressive.</KeyPoint><Para id="_378">Non-Hodgkin lymphoma grows and spreads at different rates and can be <GlossaryTermRef href="CDR0000046355" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046053" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef>. Indolent lymphoma tends to grow and spread slowly, and has few <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>. Aggressive lymphoma grows and spreads quickly, and has signs and symptoms that can be severe. The treatments for indolent and aggressive lymphoma are different.</Para><Para id="_397">This summary is about the following types of non-Hodgkin lymphoma:</Para><SummarySection id="_379"><Para id="_453"><Strong>Indolent non-Hodgkin lymphomas</Strong></Para><ItemizedList id="_398" Style="simple"><ListItem><Strong><GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">Follicular lymphoma</GlossaryTermRef>.</Strong> Follicular lymphoma is the most common type of indolent non-Hodgkin lymphoma. It is a very slow-growing type of non-Hodgkin lymphoma that begins in B lymphocytes. It  affects the lymph nodes and may spread to the bone marrow or spleen. Most patients with follicular lymphoma are age 50 years and older when they are <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef>. Follicular lymphoma may go away without treatment. The patient is closely watched for signs or symptoms that the disease has come back. Treatment is needed if signs or symptoms occur after the cancer disappeared or after initial cancer treatment. Sometimes follicular lymphoma can become a more aggressive type of lymphoma, such as <GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000409750" dictionary="Cancer.gov" audience="Patient">Lymphoplasmacytic lymphoma</GlossaryTermRef>.</Strong> In most cases of lymphoplasmacytic lymphoma,  B lymphocytes that are turning into <GlossaryTermRef href="CDR0000046230" dictionary="Cancer.gov" audience="Patient">plasma cells</GlossaryTermRef> make large amounts of a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> called <GlossaryTermRef href="CDR0000411378" dictionary="Cancer.gov" audience="Patient">monoclonal</GlossaryTermRef> <GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> M (IgM) antibody. High levels of IgM antibody in the blood cause the blood <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> to thicken. This may cause signs or symptoms such as trouble seeing or hearing, heart problems, shortness of breath, headache, dizziness, and numbness or tingling of the hands and feet. Sometimes there are no signs or symptoms of lymphoplasmacytic lymphoma. It may be found when a <GlossaryTermRef href="CDR0000688783" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef> is done for another reason. Lymphoplasmacytic lymphoma often spreads to the bone marrow, lymph nodes, and spleen. Patients with lymphoplasmacytic lymphoma should be checked for <GlossaryTermRef href="CDR0000044139" dictionary="Cancer.gov" audience="Patient">hepatitis C virus</GlossaryTermRef> infection. It is also called Waldenström macroglobulinemia.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000543124" dictionary="Cancer.gov" audience="Patient">Marginal zone lymphoma</GlossaryTermRef>.</Strong> This type of non-Hodgkin lymphoma begins in B lymphocytes in a part of lymph tissue called the marginal zone. The <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> may be worse for patients aged 70 years or older, those with <GlossaryTermRef href="CDR0000045908" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045909" dictionary="Cancer.gov" audience="Patient">stage IV</GlossaryTermRef> disease, and those with  high <GlossaryTermRef href="CDR0000354462" dictionary="Cancer.gov" audience="Patient">lactate dehydrogenase</GlossaryTermRef> (LDH) levels. There are five different types of marginal zone lymphoma. They are grouped by the type of tissue where the lymphoma formed: <ItemizedList id="_400" Style="bullet"><ListItem><Strong>Nodal marginal zone lymphoma.</Strong>  Nodal marginal zone lymphoma forms in lymph nodes. This type of non-Hodgkin lymphoma is rare. It is also called monocytoid <GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046770" dictionary="Cancer.gov" audience="Patient">Gastric</GlossaryTermRef> <GlossaryTermRef href="CDR0000044437" dictionary="Cancer.gov" audience="Patient">mucosa-associated lymphoid tissue (MALT) lymphoma</GlossaryTermRef>.</Strong> Gastric MALT lymphoma usually begins in the stomach. This type of marginal zone lymphoma  forms in cells in the <GlossaryTermRef href="CDR0000257213" dictionary="Cancer.gov" audience="Patient">mucosa</GlossaryTermRef> that help make antibodies. Patients with gastric MALT lymphoma may also have <ScientificName><GlossaryTermRef href="CDR0000045706" dictionary="Cancer.gov" audience="Patient">Helicobacter</GlossaryTermRef></ScientificName> <GlossaryTermRef href="CDR0000330169" dictionary="Cancer.gov" audience="Patient">gastritis</GlossaryTermRef> or an <GlossaryTermRef href="CDR0000045604" dictionary="Cancer.gov" audience="Patient">autoimmune disease</GlossaryTermRef>, such as <GlossaryTermRef href="CDR0000658010" dictionary="Cancer.gov" audience="Patient">Hashimoto thyroiditis</GlossaryTermRef> or <GlossaryTermRef href="CDR0000455423" dictionary="Cancer.gov" audience="Patient">Sjögren syndrome</GlossaryTermRef>. </ListItem><ListItem><Strong>Extragastric MALT lymphoma.</Strong> Extragastric MALT lymphoma begins outside of the stomach in almost every part of the body including other parts of the <GlossaryTermRef href="CDR0000046189" dictionary="Cancer.gov" audience="Patient">gastrointestinal tract</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046196" dictionary="Cancer.gov" audience="Patient">salivary glands</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046036" dictionary="Cancer.gov" audience="Patient">thyroid</GlossaryTermRef>, lung, skin, and around the eye. This type of marginal zone lymphoma  forms in cells in the mucosa that help make antibodies. Extragastric MALT lymphoma may come back many years after treatment.</ListItem><ListItem><Strong>Mediterranean <GlossaryTermRef href="CDR0000046684" dictionary="Cancer.gov" audience="Patient">abdominal</GlossaryTermRef> lymphoma.</Strong> This is a type of MALT lymphoma that occurs in young adults in eastern Mediterranean countries. It often forms in the abdomen and patients may also be infected with <GlossaryTermRef href="CDR0000044123" dictionary="Cancer.gov" audience="Patient">bacteria</GlossaryTermRef> called <Emphasis>Campylobacter jejuni</Emphasis>. This type of lymphoma is also called immunoproliferative small intestinal disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000467863" dictionary="Cancer.gov" audience="Patient">Splenic</GlossaryTermRef> marginal zone lymphoma.</Strong> This type of marginal zone lymphoma begins in the spleen and  may spread to the <GlossaryTermRef href="CDR0000046011" dictionary="Cancer.gov" audience="Patient">peripheral blood</GlossaryTermRef> and bone marrow. The most common sign of this type of splenic marginal zone lymphoma is a spleen that is larger than normal.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000748354" dictionary="Cancer.gov" audience="Patient">Primary</GlossaryTermRef> <GlossaryTermRef href="CDR0000046112" dictionary="Cancer.gov" audience="Patient">cutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000045552" dictionary="Cancer.gov" audience="Patient">anaplastic large cell lymphoma</GlossaryTermRef>.</Strong> This type of non-Hodgkin lymphoma is in the skin only. It can be a <GlossaryTermRef href="CDR0000045614" dictionary="Cancer.gov" audience="Patient">benign</GlossaryTermRef>  (not cancer) <GlossaryTermRef href="CDR0000044502" dictionary="Cancer.gov" audience="Patient">nodule</GlossaryTermRef> that may go away on its own or it can spread to many places on the skin and need treatment.</ListItem></ItemizedList></SummarySection><SummarySection id="_392"><Para id="_454"><Strong>Aggressive non-Hodgkin lymphomas</Strong></Para><ItemizedList id="_399" Style="simple"><ListItem><Strong>Diffuse large B-cell lymphoma.</Strong> Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. It grows quickly in the lymph nodes and often the spleen, liver, bone marrow, or other organs are also affected. Signs and symptoms of diffuse large B-cell lymphoma may include <GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">fever</GlossaryTermRef>,  drenching night sweats, and weight loss. These are also called B symptoms.</ListItem><ListItem><Strong>Primary mediastinal large B-cell lymphoma.</Strong> This type of non-Hodgkin lymphoma is marked by the overgrowth of <GlossaryTermRef href="CDR0000344349" dictionary="Cancer.gov" audience="Patient">fibrous</GlossaryTermRef> (scar-like) lymph tissue. A <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> most often forms behind the breastbone. It may press on the airways and cause coughing and trouble breathing. Most patients with primary mediastinal large B-cell lymphoma are women who are age 30 to 40  years.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044238" dictionary="Cancer.gov" audience="Patient">Follicular large cell lymphoma</GlossaryTermRef>, stage III.</Strong> Follicular large cell lymphoma, stage III,  is a very rare type of non-Hodgkin lymphoma. Treatment of this type of follicular lymphoma is more like treatment of aggressive NHL than of indolent NHL. </ListItem><ListItem><Strong>Anaplastic large cell lymphoma.</Strong> Anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma that usually begins in T lymphocytes. The cancer cells also have a <GlossaryTermRef href="CDR0000045776" dictionary="Cancer.gov" audience="Patient">marker</GlossaryTermRef> called CD30 on the surface of the cell.  <Para id="_409">There are two types of anaplastic large cell lymphoma:</Para><ItemizedList id="_410" Style="bullet"><ListItem><Strong>Cutaneous anaplastic large cell lymphoma.</Strong> This type of anaplastic large cell lymphoma  mostly affects the skin, but other parts of the body may also be affected. Signs of cutaneous anaplastic large cell lymphoma include one or more bumps or <GlossaryTermRef href="CDR0000390317" dictionary="Cancer.gov" audience="Patient">ulcers</GlossaryTermRef> on the skin. This type of lymphoma is rare and indolent. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045921" dictionary="Cancer.gov" audience="Patient">Systemic</GlossaryTermRef> anaplastic large cell lymphoma.</Strong> This type of anaplastic large cell lymphoma begins in the lymph nodes and may affect other parts of the body. This type of lymphoma is more aggressive.  Patients may have a lot of <GlossaryTermRef href="CDR0000045591" dictionary="Cancer.gov" audience="Patient">anaplastic</GlossaryTermRef> lymphoma <GlossaryTermRef href="CDR0000641114" dictionary="Cancer.gov" audience="Patient">kinase</GlossaryTermRef> (ALK) protein inside the lymphoma cells. These patients have a better <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> than patients who do not have extra ALK protein. Systemic anaplastic large cell lymphoma is more common in children than adults. For more information, see <SummaryRef href="CDR0000258002" url="/types/lymphoma/patient/child-nhl-treatment-pdq">Childhood Non-Hodgkin Lymphoma Treatment</SummaryRef>.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000539104" dictionary="Cancer.gov" audience="Patient">Extranodal</GlossaryTermRef> <GlossaryTermRef href="CDR0000044439" dictionary="Cancer.gov" audience="Patient">NK</GlossaryTermRef>-/<GlossaryTermRef href="CDR0000045924" dictionary="Cancer.gov" audience="Patient">T-cell lymphoma</GlossaryTermRef>.</Strong> Extranodal NK-/T-cell lymphoma usually begins in the area around the nose. It may also affect the <GlossaryTermRef href="CDR0000518299" dictionary="Cancer.gov" audience="Patient">paranasal sinus</GlossaryTermRef> (hollow spaces in the bones around the nose), roof of the mouth, <GlossaryTermRef href="CDR0000046623" dictionary="Cancer.gov" audience="Patient">trachea</GlossaryTermRef>, skin, stomach, and <GlossaryTermRef href="CDR0000046335" dictionary="Cancer.gov" audience="Patient">intestines</GlossaryTermRef>. Most cases of extranodal NK-/T-cell lymphoma have <GlossaryTermRef href="CDR0000045684" dictionary="Cancer.gov" audience="Patient">Epstein-Barr virus</GlossaryTermRef> in the tumor cells. Sometimes hemophagocytic <GlossaryTermRef href="CDR0000045090" dictionary="Cancer.gov" audience="Patient">syndrome</GlossaryTermRef>  occurs (a serious <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef> in which there are too many active histiocytes and T cells that cause severe <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef> in the body). Treatment to suppress the immune system is needed. This type of non-Hodgkin lymphoma is not common in the United States. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045766" dictionary="Cancer.gov" audience="Patient">Lymphomatoid granulomatosis</GlossaryTermRef>.</Strong> Lymphomatoid granulomatosis mostly affects the lungs. It may also affect the paranasal sinuses (hollow spaces in the bones around the nose), skin, <GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">kidneys</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef>. In lymphomatoid granulomatosis, cancer invades the <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> and kills tissue. Because the  cancer may spread to the <GlossaryTermRef href="CDR0000797669" dictionary="Cancer.gov" audience="Patient">brain</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046681" dictionary="Cancer.gov" audience="Patient">intrathecal chemotherapy</GlossaryTermRef> or <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> to the brain is given.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000346464" dictionary="Cancer.gov" audience="Patient">Angioimmunoblastic T-cell lymphoma</GlossaryTermRef>.</Strong> This type of non-Hodgkin lymphoma begins in T cells. Swollen lymph nodes are a common sign. Other signs may include a skin rash, fever, weight loss, or drenching night sweats. There may also be high levels of gamma globulin (antibodies) in the blood. Patients may also have opportunistic infections because their immune systems are weakened.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000405873" dictionary="Cancer.gov" audience="Patient">Peripheral T-cell lymphoma</GlossaryTermRef>.</Strong> Peripheral T-cell lymphoma begins in mature T lymphocytes. This type of T lymphocyte matures in the thymus <GlossaryTermRef href="CDR0000046386" dictionary="Cancer.gov" audience="Patient">gland</GlossaryTermRef> and travels to other lymphatic sites in the body such as the lymph nodes, bone marrow, and spleen. There are three subtypes of peripheral T-cell lymphoma:<ItemizedList id="_412" Style="bullet"><ListItem><Strong>Hepatosplenic T-cell lymphoma.</Strong> This is an uncommon type of peripheral T-cell lymphoma that occurs mostly in young men. It begins in the liver and spleen and the cancer cells also have a  T-cell <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptor</GlossaryTermRef> called gamma/delta on the surface of the cell.  </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">Subcutaneous</GlossaryTermRef> panniculitis-like T-cell lymphoma.</Strong> Subcutaneous panniculitis-like T-cell lymphoma begins in the skin or mucosa. It may occur with hemophagocytic syndrome (a serious condition in which there are too many active histiocytes and T cells that cause severe inflammation in the body). Treatment to suppress the immune system is needed.</ListItem><ListItem><Strong>Enteropathy-type <GlossaryTermRef href="CDR0000044046" dictionary="Cancer.gov" audience="Patient">intestinal</GlossaryTermRef> T-cell lymphoma.</Strong> This type of peripheral T-cell lymphoma occurs in the small <GlossaryTermRef href="CDR0000046500" dictionary="Cancer.gov" audience="Patient">bowel</GlossaryTermRef> of patients with untreated <GlossaryTermRef href="CDR0000377726" dictionary="Cancer.gov" audience="Patient">celiac disease</GlossaryTermRef> (an <GlossaryTermRef href="CDR0000045722" dictionary="Cancer.gov" audience="Patient">immune response</GlossaryTermRef> to gluten that causes <GlossaryTermRef href="CDR0000046014" dictionary="Cancer.gov" audience="Patient">malnutrition</GlossaryTermRef>). Patients who are diagnosed with celiac disease in childhood and stay on a gluten-free <GlossaryTermRef href="CDR0000044660" dictionary="Cancer.gov" audience="Patient">diet</GlossaryTermRef> rarely develop enteropathy-type intestinal T-cell lymphoma.</ListItem></ItemizedList></ListItem><ListItem><Strong>Intravascular large B-cell lymphoma.</Strong> This type of non-Hodgkin lymphoma affects blood vessels, especially the small blood vessels in the brain, kidney, lung, and skin. Signs and symptoms of intravascular large B-cell lymphoma are caused by blocked blood vessels. It is also called intravascular lymphomatosis.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045203" dictionary="Cancer.gov" audience="Patient">Burkitt lymphoma</GlossaryTermRef>.</Strong> Burkitt lymphoma is a type of B-cell non-Hodgkin lymphoma that grows and spreads very quickly. It may affect the jaw, bones of the face, bowel, kidneys, <GlossaryTermRef href="CDR0000046687" dictionary="Cancer.gov" audience="Patient">ovaries</GlossaryTermRef>, or other organs. There are three main types of Burkitt lymphoma (<GlossaryTermRef href="CDR0000776371" dictionary="Cancer.gov" audience="Patient">endemic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000339347" dictionary="Cancer.gov" audience="Patient">sporadic</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046357" dictionary="Cancer.gov" audience="Patient">immunodeficiency</GlossaryTermRef> related). Endemic Burkitt lymphoma commonly occurs in Africa and is linked to the Epstein-Barr virus, and sporadic Burkitt lymphoma occurs throughout the world. Immunodeficiency-related Burkitt lymphoma is most often seen in patients who have <GlossaryTermRef href="CDR0000045950" dictionary="Cancer.gov" audience="Patient">AIDS</GlossaryTermRef>. Burkitt lymphoma may spread to the brain and <GlossaryTermRef href="CDR0000340937" dictionary="Cancer.gov" audience="Patient">spinal cord</GlossaryTermRef> and treatment to <GlossaryTermRef href="CDR0000439419" dictionary="Cancer.gov" audience="Patient">prevent</GlossaryTermRef> its spread may be given. Burkitt lymphoma occurs most often in children and young adults. For more information, see <SummaryRef href="CDR0000258002" url="/types/lymphoma/patient/child-nhl-treatment-pdq">Childhood Non-Hodgkin Lymphoma Treatment</SummaryRef>. Burkitt lymphoma is also called diffuse small noncleaved-cell lymphoma.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000597158" dictionary="Cancer.gov" audience="Patient">Lymphoblastic lymphoma</GlossaryTermRef>.</Strong> Lymphoblastic lymphoma may begin in T cells or B cells, but it usually begins  in T cells. In this type of non-Hodgkin lymphoma, there are too many <GlossaryTermRef href="CDR0000302475" dictionary="Cancer.gov" audience="Patient">lymphoblasts</GlossaryTermRef> (immature white blood cells) in the lymph nodes and the thymus gland. These lymphoblasts may spread to other places in the body, such as the bone marrow, brain, and spinal cord. Lymphoblastic lymphoma is most common in teenagers and young adults. It is a lot like <GlossaryTermRef href="CDR0000045586" dictionary="Cancer.gov" audience="Patient">acute lymphoblastic leukemia</GlossaryTermRef> (lymphoblasts are mostly found in the bone marrow and blood). For more information, see <SummaryRef href="CDR0000257989" url="/types/leukemia/patient/adult-all-treatment-pdq">Acute Lymphoblastic Leukemia Treatment</SummaryRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000269410" dictionary="Cancer.gov" audience="Patient">T-cell leukemia/lymphoma</GlossaryTermRef>.</Strong> T-cell leukemia/lymphoma is caused by the <GlossaryTermRef href="CDR0000269420" dictionary="Cancer.gov" audience="Patient">human T-cell leukemia virus type 1</GlossaryTermRef> (HTLV-1). Signs include bone and skin <GlossaryTermRef href="CDR0000046324" dictionary="Cancer.gov" audience="Patient">lesions</GlossaryTermRef>, high blood <GlossaryTermRef href="CDR0000045632" dictionary="Cancer.gov" audience="Patient">calcium</GlossaryTermRef> levels, and  lymph nodes, spleen, and liver that are larger than normal. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">Mantle cell lymphoma</GlossaryTermRef>.</Strong> Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma that usually occurs in middle-aged or older adults. It begins in the lymph nodes and spreads to the spleen, bone marrow, blood, and sometimes the <GlossaryTermRef href="CDR0000046408" dictionary="Cancer.gov" audience="Patient">esophagus</GlossaryTermRef>, stomach, and intestines. Patients with mantle cell lymphoma have too much of a protein called <GlossaryTermRef href="CDR0000729820" dictionary="Cancer.gov" audience="Patient">cyclin-D1</GlossaryTermRef> or a certain <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">gene</GlossaryTermRef> change in the lymphoma cells. In some patients who do not have signs or symptoms of lymphoma, delaying the start of treatment does not affect the prognosis.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000468786" dictionary="Cancer.gov" audience="Patient">Posttransplantation lymphoproliferative disorder</GlossaryTermRef>.</Strong> This disease occurs in patients who have had a heart, lung, liver, kidney, or <GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">pancreas</GlossaryTermRef> <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplant</GlossaryTermRef> and need lifelong <GlossaryTermRef href="CDR0000045728" dictionary="Cancer.gov" audience="Patient">immunosuppressive therapy</GlossaryTermRef>. Most posttransplant lymphoproliferative disorders affect the B cells and  have Epstein-Barr virus in the cells. Lymphoproliferative disorders are often treated like cancer. </ListItem><ListItem><Strong>True <GlossaryTermRef href="CDR0000373019" dictionary="Cancer.gov" audience="Patient">histiocytic lymphoma</GlossaryTermRef>.</Strong> This is a rare, very aggressive type of lymphoma. It is not known  whether it begins in B cells or T cells. It does not respond well to treatment with standard <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000455144" dictionary="Cancer.gov" audience="Patient">Primary effusion lymphoma</GlossaryTermRef>.</Strong> Primary effusion lymphoma begins in B cells  that are found in an area where there is a large build-up of fluid, such as the areas between the lining of the lung and <GlossaryTermRef href="CDR0000044996" dictionary="Cancer.gov" audience="Patient">chest wall</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045843" dictionary="Cancer.gov" audience="Patient">pleural effusion</GlossaryTermRef>), the sac around the heart and the heart (<GlossaryTermRef href="CDR0000045825" dictionary="Cancer.gov" audience="Patient">pericardial effusion</GlossaryTermRef>), or in the abdominal <GlossaryTermRef href="CDR0000463703" dictionary="Cancer.gov" audience="Patient">cavity</GlossaryTermRef>. There is usually no tumor that can be seen. This type of lymphoma often occurs in patients who are infected with <GlossaryTermRef href="CDR0000044985" dictionary="Cancer.gov" audience="Patient">HIV</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000776368" dictionary="Cancer.gov" audience="Patient">Plasmablastic lymphoma</GlossaryTermRef>.</Strong> Plasmablastic lymphoma is a type of large B-cell non-Hodgkin lymphoma that is very aggressive. It is most often seen in patients with HIV infection.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_140"><SectMetaData><SectionType>Risk factors</SectionType></SectMetaData><KeyPoint id="_141">Older age, being male, and having a weakened immune system can increase the risk of
		  non-Hodgkin lymphoma.</KeyPoint><Para id="_142">Anything that increases a person's chance of getting a disease is called a <GlossaryTermRef href="CDR0000045873" dictionary="Cancer.gov" audience="Patient">risk factor</GlossaryTermRef>. Not every person with one or more of these risk factors will develop non-Hodgkin lymphoma, and it can develop in people who don't have any known risk factors. Talk with your doctor if you think you may be at risk. </Para><Para id="_413">These and other risk factors may increase the risk of certain types of non-Hodgkin lymphoma:</Para><ItemizedList id="_143" Style="bullet"> 
		   
		  <ListItem>Being older, male, or White.</ListItem> 
		  <ListItem>Having one of the following medical conditions that weakens the immune system:<ItemizedList id="_144" Style="dash"><ListItem>An <GlossaryTermRef href="CDR0000045098" dictionary="Cancer.gov" audience="Patient">inherited</GlossaryTermRef> immune <GlossaryTermRef href="CDR0000407758" dictionary="Cancer.gov" audience="Patient">disorder</GlossaryTermRef> (such as <GlossaryTermRef href="CDR0000455335" dictionary="Cancer.gov" audience="Patient">hypogammaglobulinemia</GlossaryTermRef> or <GlossaryTermRef href="CDR0000539110" dictionary="Cancer.gov" audience="Patient">Wiskott-Aldrich syndrome</GlossaryTermRef>).</ListItem><ListItem>An autoimmune disease (such as <GlossaryTermRef href="CDR0000455398" dictionary="Cancer.gov" audience="Patient">rheumatoid arthritis</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044219" dictionary="Cancer.gov" audience="Patient">psoriasis</GlossaryTermRef>, or Sjögren syndrome).</ListItem><ListItem>HIV/AIDS.</ListItem><ListItem>Human T-lymphotrophic virus type I or Epstein-Barr virus infection.</ListItem><ListItem><ScientificName>Helicobacter pylori</ScientificName> infection.</ListItem></ItemizedList></ListItem> 
		   
		   
		  <ListItem>Taking <GlossaryTermRef href="CDR0000045727" dictionary="Cancer.gov" audience="Patient">immunosuppressant</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> after an organ transplant.</ListItem> 
		</ItemizedList></SummarySection><SummarySection id="_145"><SectMetaData><SectionType>Symptoms</SectionType></SectMetaData><KeyPoint id="_146">Signs and symptoms of non-Hodgkin lymphoma include swollen lymph nodes, fever,
		  drenching night sweats, weight loss, and fatigue. </KeyPoint><Para id="_147">These signs and symptoms may be caused by non-Hodgkin
		  lymphoma or by other conditions. Check with your doctor if you have any of the
		  following:</Para><ItemizedList id="_148" Style="bullet"> 
		  <ListItem>Swelling in the lymph nodes in the neck, underarm,
			  groin, or stomach.</ListItem> 
		  <ListItem>Fever for no known reason.</ListItem> 
		  <ListItem>Drenching night sweats.</ListItem> 
		  <ListItem>Feeling very tired.</ListItem> 
		  <ListItem>Weight loss for no known reason.</ListItem> 
		  <ListItem>Skin rash or itchy skin.</ListItem><ListItem>Pain in the chest, abdomen, or bones for no known reason.</ListItem> 
		</ItemizedList><Para id="_411">When fever, drenching night sweats, and weight loss occur together, this group of symptoms is called B symptoms. </Para><Para id="_415">Other signs and symptoms of non-Hodgkin lymphoma may occur and depend on the following:

</Para><ItemizedList id="_416" Style="bullet"><ListItem>Where the cancer forms in the body.</ListItem><ListItem>The size of the tumor.</ListItem><ListItem>How fast the tumor grows.
</ListItem></ItemizedList></SummarySection><SummarySection id="_149"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_150">Tests that examine the lymph system and other parts of the body are used to  diagnose and stage non-Hodgkin lymphoma.</KeyPoint><Para id="_151">In addition to asking about your <GlossaryTermRef href="CDR0000642019" dictionary="Cancer.gov" audience="Patient">personal</GlossaryTermRef> and <GlossaryTermRef href="CDR0000642015" dictionary="Cancer.gov" audience="Patient">family health history</GlossaryTermRef> and doing a <GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">physical exam</GlossaryTermRef>, your doctor may perform the following tests and procedures:</Para><ItemizedList id="_152" Style="bullet"> 
		   
		  <ListItem><Strong><GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">Complete blood count</GlossaryTermRef> (CBC)</Strong>: A  procedure in which a sample of blood is drawn and checked for the following:<ItemizedList id="_24" Style="dash"><ListItem>The number of red blood cells, white blood cells, and platelets.</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the protein that carries <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef>) in the red blood cells.</ListItem><ListItem>The portion of the sample made up of red blood cells.</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells." language="en" placement="image-center" id="_490"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">Blood chemistry studies</GlossaryTermRef></Strong>: A procedure in which a blood sample is checked to measure the amounts of certain substances released into the blood by
			 organs and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign
			 of disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000354465" dictionary="Cancer.gov" audience="Patient">LDH</GlossaryTermRef> test</Strong>: A procedure in which a blood sample is checked to measure the amount  of lactic dehydrogenase. An increased amount of LDH in the blood may be a sign of tissue damage, lymphoma, or other diseases.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046146" dictionary="Cancer.gov" audience="Patient">Hepatitis B</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044139" dictionary="Cancer.gov" audience="Patient">hepatitis C</GlossaryTermRef> test</Strong>: A procedure in which a sample of blood is checked to measure the amounts of hepatitis B virus-specific <GlossaryTermRef href="CDR0000046086" dictionary="Cancer.gov" audience="Patient">antigens</GlossaryTermRef> and/or antibodies and the amounts of hepatitis C virus-specific antibodies. These antigens or antibodies are called markers. Different markers or combinations of markers are used to determine whether a patient has a hepatitis B or C infection, has had a prior infection or <GlossaryTermRef href="CDR0000045937" dictionary="Cancer.gov" audience="Patient">vaccination</GlossaryTermRef>, or is susceptible to infection. Patients who have been treated for hepatitis B virus in the past need continued <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitoring</GlossaryTermRef> to check if it has <GlossaryTermRef href="CDR0000683532" dictionary="Cancer.gov" audience="Patient">reactivated</GlossaryTermRef>. Knowing whether a person has hepatitis B or C may help plan treatment.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000759626" dictionary="Cancer.gov" audience="Patient">HIV test</GlossaryTermRef></Strong>: A test to measure the level of HIV antibodies in a sample of blood.  Antibodies are made by the body when it is invaded by a <GlossaryTermRef href="CDR0000698772" dictionary="Cancer.gov" audience="Patient">foreign</GlossaryTermRef> substance. A high level of HIV antibodies may mean the body has been infected with HIV.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046033" dictionary="Cancer.gov" audience="Patient">CT scan</GlossaryTermRef> (CAT scan)</Strong>:
		  A procedure that makes a series of detailed pictures of areas inside the body, such as the neck, chest, abdomen, pelvis, and lymph nodes, taken from different angles.  The pictures are made by a computer linked to an <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-ray</GlossaryTermRef> machine. A <GlossaryTermRef href="CDR0000409764" dictionary="Cancer.gov" audience="Patient">dye</GlossaryTermRef> may be <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef> or swallowed to help the organs or tissues show up more clearly.  This procedure is also called computed tomography, computerized tomography, or computerized axial tomography.</ListItem> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000046140" dictionary="Cancer.gov" audience="Patient">PET scan</GlossaryTermRef> (positron
		  emission tomography scan)</Strong>: A procedure to find <GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> tumor cells in the body.  A small amount of <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> <GlossaryTermRef href="CDR0000044033" dictionary="Cancer.gov" audience="Patient">glucose</GlossaryTermRef> (sugar) is injected into a vein.  The PET <GlossaryTermRef href="CDR0000386220" dictionary="Cancer.gov" audience="Patient">scanner</GlossaryTermRef> rotates around the body and makes a picture of where glucose is being used in the body.  Malignant tumor cells show up brighter in the picture because they are more active and take up more glucose than normal cells do.</ListItem><ListItem> <Strong><GlossaryTermRef href="CDR0000046505" dictionary="Cancer.gov" audience="Patient">Bone marrow aspiration</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046506" dictionary="Cancer.gov" audience="Patient">biopsy</GlossaryTermRef></Strong>: The removal of bone marrow and a small piece of bone by inserting a needle into the hipbone or breastbone. A <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef> views the bone marrow and bone under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> to look for signs of cancer.<MediaLink ref="CDR0000554337" type="image/jpeg" alt="Bone marrow aspiration and biopsy; drawing shows a patient lying face down on a table and a bone marrow needle being inserted into the hip bone. An inset shows a close up of the needle being inserted through the skin and hip bone into the bone marrow." language="en" placement="image-center" id="_310"><Caption language="en">Bone marrow aspiration and biopsy. After a small area of skin is numbed, a long, hollow needle is inserted through the patient's skin and hip bone into the bone marrow. A sample of bone marrow and a small piece of bone are removed for examination under a microscope.</Caption></MediaLink></ListItem><ListItem><Strong> Lymph node biopsy</Strong>: The
			 removal of all or part of a  lymph node. A pathologist views the tissue under a microscope to check for cancer cells. One of the following  types of biopsies  may be done:   <ItemizedList id="_154" Style="dash"> 
				<ListItem><Strong><GlossaryTermRef href="CDR0000046411" dictionary="Cancer.gov" audience="Patient">Excisional
				  biopsy</GlossaryTermRef></Strong>: The removal of an entire lymph node. </ListItem> 
				<ListItem><Strong><GlossaryTermRef href="CDR0000046698" dictionary="Cancer.gov" audience="Patient">Incisional
				  biopsy</GlossaryTermRef></Strong>: The removal of part of a lymph node.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045657" dictionary="Cancer.gov" audience="Patient">Core biopsy</GlossaryTermRef></Strong>:  The removal of part of a lymph node using a wide needle.  </ListItem> 
				 
				</ItemizedList></ListItem> 
		</ItemizedList><Para id="_319">If cancer is found, the following tests may be done to study the cancer cells:

</Para><ItemizedList id="_320" Style="bullet"><ListItem><Strong><GlossaryTermRef href="CDR0000653117" dictionary="Cancer.gov" audience="Patient">Immunohistochemistry</GlossaryTermRef></Strong>:  A <GlossaryTermRef href="CDR0000046590" dictionary="Cancer.gov" audience="Patient">laboratory test</GlossaryTermRef> that uses antibodies to check for certain antigens (markers) in a sample of a patient’s tissue. The antibodies are usually linked to an <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzyme</GlossaryTermRef> or a fluorescent dye. After the antibodies bind to a specific antigen in the tissue sample, the enzyme or dye is activated, and the antigen can then be seen under a microscope. This type of test is used to help diagnose cancer and to help tell one type of cancer from another type of cancer.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000270737" dictionary="Cancer.gov" audience="Patient">Cytogenetic analysis</GlossaryTermRef></Strong>: A laboratory test in which the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef> of cells in a sample of blood or bone marrow are counted and checked for any changes, such as broken, missing, rearranged, or extra chromosomes. Changes in certain chromosomes may be a sign of cancer. Cytogenetic analysis is used to help diagnose cancer, plan treatment, or find out how well treatment is working.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000341450" dictionary="Cancer.gov" audience="Patient">Immunophenotyping</GlossaryTermRef></Strong>: A laboratory test that uses antibodies to identify cancer cells based on the types of antigens or markers on the surface of the cells. This test is used to help diagnose specific types of lymphoma.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000460228" dictionary="Cancer.gov" audience="Patient">FISH</GlossaryTermRef> (fluorescence in situ hybridization)</Strong>: A laboratory test used to look at and count genes or chromosomes in cells and tissues. Pieces of <GlossaryTermRef href="CDR0000045671" dictionary="Cancer.gov" audience="Patient">DNA</GlossaryTermRef> that contain fluorescent dyes are made in the laboratory and added to a sample of a patient’s cells or tissues. When these dyed pieces of DNA attach to certain genes or areas of chromosomes in the sample, they light up when viewed under a fluorescent microscope. The FISH test is used to help diagnose cancer and help plan treatment.</ListItem></ItemizedList><Para id="_417">Other tests and procedures may be done depending on the signs and symptoms seen and where the cancer forms in the body.</Para></SummarySection><SummarySection id="_155"><SectMetaData><SectionType>Prognostic factors</SectionType></SectMetaData><KeyPoint id="_156">Certain factors affect prognosis (chance
		  of recovery) and treatment options.</KeyPoint><Para id="_260">The prognosis and treatment options depend on the following:</Para><ItemizedList id="_261" Style="bullet"><ListItem>The patient's signs and symptoms, including whether or not they have B symptoms (fever for no known reason, weight loss for no known reason, or drenching  night sweats).</ListItem><ListItem>The <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the cancer (the size of the cancer tumors and whether the cancer has spread to other parts of the body or lymph nodes).</ListItem><ListItem>The type of non-Hodgkin lymphoma.  </ListItem><ListItem>The amount of lactate dehydrogenase (LDH) in the blood.</ListItem><ListItem>Whether there are certain changes in the genes.</ListItem><ListItem>The patient’s age, sex, and
		  general health.</ListItem><ListItem>Whether the lymphoma is newly diagnosed, continues to grow during treatment, or has <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurred</GlossaryTermRef> (come back).</ListItem></ItemizedList><Para id="_275">For non-Hodgkin lymphoma during pregnancy, treatment options also depend on:</Para><ItemizedList id="_276" Style="bullet"><ListItem>The wishes of the patient.</ListItem><ListItem>Which trimester of pregnancy the patient is in.</ListItem><ListItem>Whether the baby can be delivered early.</ListItem></ItemizedList><Para id="_277">Some types of non-Hodgkin lymphoma spread more quickly than
		  others do. Most non-Hodgkin lymphomas that occur during pregnancy are
		  aggressive. Delaying treatment
		  of aggressive lymphoma until after the baby is born may lessen the mother's chance of survival. Immediate
		  treatment is often recommended, even during pregnancy. </Para></SummarySection></SummarySection><SummarySection id="_158"><Title>Stages of Non-Hodgkin Lymphoma</Title><SummarySection id="_159"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_160">After non-Hodgkin lymphoma has been diagnosed, tests are done to find out
		  whether cancer cells have spread within the lymph
		  system or to other parts of the body.
		  </KeyPoint><Para id="_161">The process used to find out the type of <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> and if cancer <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>
		  have spread within the <GlossaryTermRef href="CDR0000045764" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef> or to other parts of the body is called <GlossaryTermRef href="CDR0000046597" dictionary="Cancer.gov" audience="Patient">staging</GlossaryTermRef>. The
		  information gathered from the staging process determines the <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the
		  disease. It is important to know the stage of the disease in order to plan treatment. The results of the <SummaryRef href="CDR0000062958#_150" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">tests and procedures</SummaryRef> done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> are used to help make decisions about treatment.</Para><Para id="_418">The following tests and procedures may also be used in the staging
		  process:</Para><ItemizedList id="_163" Style="bullet"> 
		   
		   
		   
		  <ListItem><Strong><GlossaryTermRef href="CDR0000045788" dictionary="Cancer.gov" audience="Patient">MRI</GlossaryTermRef> (magnetic
		  resonance imaging) with <GlossaryTermRef href="CDR0000597153" dictionary="Cancer.gov" audience="Patient">gadolinium</GlossaryTermRef></Strong>: A procedure that uses a magnet, <GlossaryTermRef href="CDR0000651209" dictionary="Cancer.gov" audience="Patient">radio waves</GlossaryTermRef>, and a computer to make a series of detailed pictures of areas inside the body, such as the <GlossaryTermRef href="CDR0000797669" dictionary="Cancer.gov" audience="Patient">brain</GlossaryTermRef> and <GlossaryTermRef href="CDR0000340937" dictionary="Cancer.gov" audience="Patient">spinal cord</GlossaryTermRef>. A substance called gadolinium is <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into the patient through a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef>. The gadolinium collects around the cancer cells so they show up brighter in the picture. This procedure is also called nuclear magnetic resonance imaging (NMRI).</ListItem> 
		   
		<ListItem><Strong><GlossaryTermRef href="CDR0000046303" dictionary="Cancer.gov" audience="Patient">Lumbar puncture</GlossaryTermRef></Strong>: A procedure used to collect <GlossaryTermRef href="CDR0000046483" dictionary="Cancer.gov" audience="Patient">cerebrospinal fluid</GlossaryTermRef> (CSF) from the <GlossaryTermRef href="CDR0000396787" dictionary="Cancer.gov" audience="Patient">spinal column</GlossaryTermRef>. This is done by placing a needle between two bones in the <GlossaryTermRef href="CDR0000415914" dictionary="Cancer.gov" audience="Patient">spine</GlossaryTermRef> and into the CSF around the spinal cord and removing a sample of the fluid.  The sample of CSF is checked under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> for signs that the cancer has spread to the brain and spinal cord. This procedure is also called an LP or spinal tap. <MediaLink ref="CDR0000503953" type="image/jpeg" alt="Lumbar puncture; drawing shows a patient lying in a curled position on a table and a spinal needle (a long, thin needle) being inserted into the lower back. Inset shows a close-up of the spinal needle inserted into the cerebrospinal fluid (CSF) in the lower part of the spinal column." language="en" placement="image-center" id="_322"><Caption language="en">Lumbar puncture. A patient lies in a curled position on a table. After a small area on the lower back is numbed, a spinal needle (a long, thin needle) is inserted into the lower part of the spinal column to remove cerebrospinal fluid (CSF, shown in blue). The fluid may be sent to a laboratory for testing.</Caption></MediaLink></ListItem></ItemizedList><Para id="_284">For <GlossaryTermRef href="CDR0000666677" dictionary="Cancer.gov" audience="Patient">pregnant</GlossaryTermRef> women with non-Hodgkin lymphoma, staging tests and procedures that protect the <GlossaryTermRef href="CDR0000046400" dictionary="Cancer.gov" audience="Patient">fetus</GlossaryTermRef> from the harms of  <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> are used. These tests and procedures include MRI (without contrast), lumbar puncture, and <GlossaryTermRef href="CDR0000046157" dictionary="Cancer.gov" audience="Patient">ultrasound</GlossaryTermRef>.  </Para></SummarySection><SummarySection id="_302"><KeyPoint id="_303">There are three ways that cancer spreads in the body.</KeyPoint><Para id="_302_md_69">Cancer can spread through <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000045764" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>, and the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef>:</Para><ItemizedList id="_302_md_70" Style="bullet"><ListItem>Tissue. The cancer spreads from where it began by growing into nearby areas.
</ListItem><ListItem>Lymph system. The cancer spreads from where it began by getting into the lymph system. The cancer travels through the <GlossaryTermRef href="CDR0000269462" dictionary="Cancer.gov" audience="Patient">lymph vessels</GlossaryTermRef> to other parts of the body.
</ListItem><ListItem>Blood. The cancer spreads from where it began by getting into the blood. The cancer travels through the <GlossaryTermRef href="CDR0000045020" dictionary="Cancer.gov" audience="Patient">blood vessels</GlossaryTermRef> to other parts of the body.
</ListItem></ItemizedList></SummarySection><SummarySection id="_164"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_165">The following stages are used for non-Hodgkin
		  lymphoma:</KeyPoint><SummarySection id="_166"><KeyPoint id="_167">Stage I</KeyPoint><MediaLink ref="CDR0000614643" type="image/jpeg" alt="Stage I adult lymphoma; drawing shows cancer in one lymph node group and in the spleen. Also shown are the Waldeyer’s ring and the thymus. An inset shows a lymph node with a lymph vessel, an artery, and a vein. Cancer cells are shown in the lymph node." language="en" placement="image-center" id="_497"><Caption language="en">Stage I adult lymphoma. Cancer is found in one or more lymph nodes in a group of lymph nodes or, in rare cases, cancer is found in the Waldeyer’s ring, thymus, or spleen. In stage IE (not shown), cancer has spread to one area outside the lymph system.</Caption></MediaLink><Para id="_479"><GlossaryTermRef href="CDR0000045906" dictionary="Cancer.gov" audience="Patient">Stage I non-Hodgkin lymphoma</GlossaryTermRef> is divided into stages I and IE.</Para><Para id="_480">In stage I, <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> is found in one of the following places in the <GlossaryTermRef href="CDR0000793442" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>:</Para><ItemizedList id="_481" Style="bullet">
     <ListItem>One or more <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> in a group of lymph nodes.</ListItem><ListItem><GlossaryTermRef href="CDR0000777073" dictionary="Cancer.gov" audience="Patient">Waldeyer's ring</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046616" dictionary="Cancer.gov" audience="Patient">Thymus</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">Spleen</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_482">In stage IE, cancer is found in one area outside the lymph system.</Para></SummarySection><SummarySection id="_170"><KeyPoint id="_171">Stage II</KeyPoint><Para id="_483"><GlossaryTermRef href="CDR0000045907" dictionary="Cancer.gov" audience="Patient">Stage II non-Hodgkin lymphoma</GlossaryTermRef> is divided into stages II and IIE.</Para><ItemizedList id="_484" Style="bullet">
     <ListItem>In stage II, <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> is found in two or more groups of <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> that are either above the <GlossaryTermRef href="CDR0000046451" dictionary="Cancer.gov" audience="Patient">diaphragm</GlossaryTermRef> or below the diaphragm. <MediaLink ref="CDR0000614648" type="image/jpeg" alt="Stage II adult lymphoma; drawing shows cancer in two lymph node groups above the diaphragm and below the diaphragm. An inset shows a lymph node with a lymph vessel, an artery, and a vein. Cancer cells are shown in the lymph node." language="en" placement="image-center" id="_498"><Caption language="en">Stage II adult lymphoma. Cancer is found in two or more groups of lymph nodes that are either above the diaphragm or below the diaphragm. </Caption></MediaLink></ListItem><ListItem>In stage IIE, cancer has spread from a group of lymph nodes to a nearby area that is outside the <GlossaryTermRef href="CDR0000793442" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>. Cancer may have spread to other lymph node groups on the same side of the diaphragm.

<MediaLink ref="CDR0000614650" type="image/jpeg" alt="Stage IIE adult lymphoma; drawing shows cancer that has spread from a group of lymph nodes to a nearby area. Also shown is a lung and the diaphragm. An inset shows a lymph node with a lymph vessel, an artery, and a vein. Cancer cells are shown in the lymph node." language="en" placement="image-center" id="_499"><Caption language="en">Stage IIE adult lymphoma. Cancer has spread from a group of lymph nodes to a nearby area that is outside the lymph system. Cancer may have spread to other lymph node groups on the same side of the diaphragm.</Caption></MediaLink></ListItem></ItemizedList><Para id="_485">In stage II, the term <Emphasis>bulky disease</Emphasis> refers to a larger <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> mass. The size of the tumor mass that is referred to as bulky disease varies based on the type of <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>. 


</Para></SummarySection><SummarySection id="_174"><KeyPoint id="_175">Stage III </KeyPoint><MediaLink ref="CDR0000614684" type="image/jpeg" alt="Stage III adult lymphoma; drawing shows the right and left sides of the body. The right side of the body shows cancer in a group of lymph nodes above the diaphragm and below the diaphragm. The left side of the body shows cancer in a group of lymph nodes above the diaphragm and cancer in the spleen." language="en" placement="image-center" id="_500"><Caption language="en">Stage III adult lymphoma. Cancer is found in groups of lymph nodes both above and below the diaphragm; or in a group of lymph nodes above the diaphragm and in the spleen.</Caption></MediaLink><Para id="_486">In <GlossaryTermRef href="CDR0000045908" dictionary="Cancer.gov" audience="Patient">stage III non-Hodgkin lymphoma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> is found:</Para><ItemizedList id="_487" Style="bullet">
     <ListItem>in groups of <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> both above and below the <GlossaryTermRef href="CDR0000046451" dictionary="Cancer.gov" audience="Patient">diaphragm</GlossaryTermRef>; or</ListItem><ListItem>in lymph nodes above the diaphragm and in the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_178"><KeyPoint id="_179">Stage IV</KeyPoint><MediaLink ref="CDR0000629626" type="image/jpeg" alt="Stage IV adult lymphoma; drawing shows four panels: (a) the top left panel shows cancer in the liver; (b) the top right panel shows cancer in the left lung and in two groups of lymph nodes below the diaphragm; (c) the bottom left panel shows cancer in the left lung and in a group of lymph nodes above the diaphragm and below the diaphragm; and (d) the bottom right panel shows cancer in both lungs, the liver, and the bone marrow (pullout). Also shown is primary cancer in the lymph nodes and a pullout of the brain with cerebrospinal fluid (in blue)." language="en" placement="image-center" id="_501"><Caption language="en">Stage IV adult lymphoma. Cancer (a) has spread throughout one or more organs outside the lymph system; or (b) is found in two or more groups of lymph nodes that are either above the diaphragm or below the diaphragm and in one organ that is outside the lymph system and not near the affected lymph nodes; or (c) is found in groups of lymph nodes above the diaphragm and below the diaphragm and in any organ that is outside the lymph system; or (d) is found in the liver, bone marrow, more than one place in the lung, or cerebrospinal fluid (CSF). The cancer has not spread directly into the liver, bone marrow, lung, or CSF from nearby lymph nodes.</Caption></MediaLink><Para id="_488">In <GlossaryTermRef href="CDR0000045909" dictionary="Cancer.gov" audience="Patient">stage IV non-Hodgkin lymphoma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>:</Para><ItemizedList id="_489" Style="bullet">
     <ListItem>has spread throughout one or more <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> outside the <GlossaryTermRef href="CDR0000793442" dictionary="Cancer.gov" audience="Patient">lymph system</GlossaryTermRef>; or</ListItem><ListItem>is found in two or more groups of <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> that are either above the <GlossaryTermRef href="CDR0000046451" dictionary="Cancer.gov" audience="Patient">diaphragm</GlossaryTermRef> or below the diaphragm and in one organ that is outside the lymph system and not near the affected lymph nodes; or</ListItem><ListItem>is found in groups of lymph nodes both above and below the diaphragm and in any organ that is outside the lymph system; or</ListItem><ListItem>is found in the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>, more than one place in the <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046483" dictionary="Cancer.gov" audience="Patient">cerebrospinal fluid</GlossaryTermRef> (CSF). The cancer has not spread directly into the liver, bone marrow, lung, or CSF from nearby lymph nodes.

</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_182"><KeyPoint id="_183">Non-Hodgkin lymphomas may be grouped for treatment according to whether the cancer is indolent or aggressive, whether affected lymph nodes are next to each other in the body, and whether the cancer is newly diagnosed or recurrent.</KeyPoint><Para id="_414">For more information on the types of <GlossaryTermRef href="CDR0000045735" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef> (slow-growing) and <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef> (fast-growing) non-Hodgkin lymphoma, see the <SummaryRef href="CDR0000062958#_376" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">General Information</SummaryRef> section.</Para><Para id="_186">Non-Hodgkin lymphoma can also be described as <GlossaryTermRef href="CDR0000350356" dictionary="Cancer.gov" audience="Patient">contiguous</GlossaryTermRef> or <GlossaryTermRef href="CDR0000350357" dictionary="Cancer.gov" audience="Patient">noncontiguous</GlossaryTermRef>:</Para><ItemizedList id="_187" Style="bullet"><ListItem>Contiguous lymphomas: <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">Lymphomas</GlossaryTermRef> in which the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> with cancer are next
		  to each other.</ListItem><ListItem> Noncontiguous lymphomas: Lymphomas in which the lymph nodes with cancer
		  are not next to each other, but are on the same side of the
		  <GlossaryTermRef href="CDR0000046451" dictionary="Cancer.gov" audience="Patient">diaphragm</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_314"><KeyPoint id="_315">Non-Hodgkin lymphoma  can recur (come back) after it has been treated.</KeyPoint><Para id="_316"> The lymphoma may come back
		in the lymph system or in other parts of the body. Indolent lymphoma may come back as
		aggressive lymphoma. Aggressive
		lymphoma may come back as indolent lymphoma.</Para></SummarySection></SummarySection><SummarySection id="_190"><Title>Treatment Option Overview</Title><SummarySection id="_191"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_192">There are different types of treatment for patients with non-Hodgkin lymphoma. </KeyPoint><Para id="_193">Different types of treatment are available for patients with <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef>. Some treatments are <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment), and some
		  are being tested in <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>.
		  A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research study</GlossaryTermRef> meant to help
		  improve current treatments or obtain information on new treatments for patients
		  with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. When clinical trials show that a new treatment is better than the
		  standard treatment, the new
		  treatment may become the standard treatment.    Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.</Para><Para id="_285">For <GlossaryTermRef href="CDR0000666677" dictionary="Cancer.gov" audience="Patient">pregnant</GlossaryTermRef> women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the <GlossaryTermRef href="CDR0000046400" dictionary="Cancer.gov" audience="Patient">fetus</GlossaryTermRef>. Treatment decisions are based on the mother’s wishes, the <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the non-Hodgkin lymphoma, and the trimester of the pregnancy. The treatment plan may change as the <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>, cancer, and pregnancy change. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.
</Para></SummarySection><SummarySection id="_62"><KeyPoint id="_63">Patients with non-Hodgkin lymphoma should have their treatment
		  planned by a team of health care providers who are experts in treating lymphomas.</KeyPoint><Para id="_64">Treatment will be overseen by a <GlossaryTermRef href="CDR0000046290" dictionary="Cancer.gov" audience="Patient">medical
		  oncologist</GlossaryTermRef>, a doctor who specializes in treating cancer, or a <GlossaryTermRef href="CDR0000046370" dictionary="Cancer.gov" audience="Patient">hematologist</GlossaryTermRef>, a doctor who specializes in treating <GlossaryTermRef href="CDR0000733834" dictionary="Cancer.gov" audience="Patient">blood cancers</GlossaryTermRef>. The
		  medical oncologist may refer you to other    <GlossaryTermRef href="CDR0000650566" dictionary="Cancer.gov" audience="Patient">health care providers</GlossaryTermRef> who have experience and
		  are experts in treating non-Hodgkin lymphoma and who specialize in certain
		  areas of <GlossaryTermRef href="CDR0000482419" dictionary="Cancer.gov" audience="Patient">medicine</GlossaryTermRef>. These may include the following <GlossaryTermRef href="CDR0000478785" dictionary="Cancer.gov" audience="Patient">specialists</GlossaryTermRef>:</Para><ItemizedList id="_65" Style="bullet"> 
		  <ListItem><GlossaryTermRef href="CDR0000046269" dictionary="Cancer.gov" audience="Patient">Neurosurgeon</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046267" dictionary="Cancer.gov" audience="Patient">Neurologist</GlossaryTermRef>.</ListItem> 
		   
		  <ListItem><GlossaryTermRef href="CDR0000046546" dictionary="Cancer.gov" audience="Patient">Radiation
			 oncologist</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046439" dictionary="Cancer.gov" audience="Patient">Endocrinologist</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000318825" dictionary="Cancer.gov" audience="Patient">Rehabilitation specialist</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000809738" dictionary="Cancer.gov" audience="Patient">Fertility specialist</GlossaryTermRef>.</ListItem><ListItem>Other <GlossaryTermRef href="CDR0000045434" dictionary="Cancer.gov" audience="Patient">oncology</GlossaryTermRef> specialists.</ListItem> 
		</ItemizedList></SummarySection><SummarySection id="_362"><KeyPoint id="_363">Treatment for non-Hodgkin lymphoma may cause side effects.</KeyPoint><Para id="_362_md_76">To learn more about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> that begin during treatment for cancer, visit <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef>.</Para><Para id="_364">Side effects from cancer treatment that begin after treatment and continue for months or years are called <GlossaryTermRef href="CDR0000390292" dictionary="Cancer.gov" audience="Patient">late effects</GlossaryTermRef>. Treatment with <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef> for non-Hodgkin lymphoma may increase the risk of  late effects. </Para><Para id="_405">Late effects of cancer treatment may include the following: </Para><ItemizedList id="_395" Style="bullet"><ListItem>Heart problems.</ListItem><ListItem><GlossaryTermRef href="CDR0000046348" dictionary="Cancer.gov" audience="Patient">Infertility</GlossaryTermRef> (inability to have children).</ListItem><ListItem>Loss of <GlossaryTermRef href="CDR0000407755" dictionary="Cancer.gov" audience="Patient">bone density</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046041" dictionary="Cancer.gov" audience="Patient">Neuropathy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000373935" dictionary="Cancer.gov" audience="Patient">nerve</GlossaryTermRef> damage that causes numbness or trouble walking).</ListItem><ListItem>A <GlossaryTermRef href="CDR0000046658" dictionary="Cancer.gov" audience="Patient">second cancer</GlossaryTermRef>, such as:<ItemizedList id="_396" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000445043" dictionary="Cancer.gov" audience="Patient">Lung cancer</GlossaryTermRef>.</ListItem><ListItem>Brain cancer.</ListItem><ListItem><GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">Kidney cancer</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000444968" dictionary="Cancer.gov" audience="Patient">Bladder cancer</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">Melanoma</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000270800" dictionary="Cancer.gov" audience="Patient">Hodgkin lymphoma</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">Myelodysplastic syndrome</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">Acute myeloid leukemia</GlossaryTermRef>.</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_250">Some late effects may be treated or controlled. It is important to talk with your doctor about the effects cancer treatment can have on you. Regular <GlossaryTermRef href="CDR0000044671" dictionary="Cancer.gov" audience="Patient">follow-up</GlossaryTermRef> to check for late effects is important.</Para></SummarySection><SummarySection id="_195"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_196">The following types of treatment are used:</KeyPoint><SummarySection id="_197"><KeyPoint id="_198">Radiation therapy
			 </KeyPoint><Para id="_199">Radiation therapy is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> or keep them from growing. </Para><Para id="_506"><GlossaryTermRef href="CDR0000046686" dictionary="Cancer.gov" audience="Patient">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes <GlossaryTermRef href="CDR0000045930" dictionary="Cancer.gov" audience="Patient">total-body irradiation</GlossaryTermRef> is given before a <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</Para><Para id="_505"><GlossaryTermRef href="CDR0000270726" dictionary="Cancer.gov" audience="Patient">Proton beam radiation therapy</GlossaryTermRef>  is a type of high-energy, external radiation therapy that uses streams of <GlossaryTermRef href="CDR0000044715" dictionary="Cancer.gov" audience="Patient">protons</GlossaryTermRef> (tiny particles with a positive charge) to kill <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> cells. This type of treatment can lower the amount of radiation damage to healthy <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissue</GlossaryTermRef> near a tumor such as the heart or <GlossaryTermRef href="CDR0000304766" dictionary="Cancer.gov" audience="Patient">breast</GlossaryTermRef>.</Para><Para id="_463">External radiation therapy is used to treat non-Hodgkin lymphoma, and may also be used as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to relieve symptoms and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</Para><Para id="_294">For a pregnant woman with non-Hodgkin lymphoma, radiation therapy should be given after delivery, if possible, to avoid any risk to the fetus. If treatment is needed right away, the woman  may decide to continue the pregnancy and receive radiation therapy. A <GlossaryTermRef href="CDR0000798602" dictionary="Cancer.gov" audience="Patient">lead shield</GlossaryTermRef> is used to cover the pregnant woman's <GlossaryTermRef href="CDR0000045070" dictionary="Cancer.gov" audience="Patient">abdomen</GlossaryTermRef> to help protect the fetus from radiation as much as possible. </Para></SummarySection><SummarySection id="_200"><KeyPoint id="_201">Chemotherapy </KeyPoint><Para id="_202">Chemotherapy is a cancer treatment that uses <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.   When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef> or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef>). When chemotherapy is placed directly into the <GlossaryTermRef href="CDR0000046483" dictionary="Cancer.gov" audience="Patient">cerebrospinal fluid</GlossaryTermRef> (<GlossaryTermRef href="CDR0000046681" dictionary="Cancer.gov" audience="Patient">intrathecal chemotherapy</GlossaryTermRef>), an <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organ</GlossaryTermRef>, or a body <GlossaryTermRef href="CDR0000463703" dictionary="Cancer.gov" audience="Patient">cavity</GlossaryTermRef> such as the abdomen, the drugs mainly affect cancer cells in those areas (<GlossaryTermRef href="CDR0000046559" dictionary="Cancer.gov" audience="Patient">regional chemotherapy</GlossaryTermRef>). <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> is treatment using two or more anticancer drugs. <GlossaryTermRef href="CDR0000046601" dictionary="Cancer.gov" audience="Patient">Steroid drugs</GlossaryTermRef> may be added, to lessen
			 <GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef> and lower the body's <GlossaryTermRef href="CDR0000045722" dictionary="Cancer.gov" audience="Patient">immune response</GlossaryTermRef>.</Para><Para id="_448">Systemic combination chemotherapy is used for the treatment of non-Hodgkin lymphoma.</Para><Para id="_263">Intrathecal chemotherapy may also be used in the treatment of <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef> that first forms in the <GlossaryTermRef href="CDR0000046611" dictionary="Cancer.gov" audience="Patient">testicles</GlossaryTermRef> or <GlossaryTermRef href="CDR0000641960" dictionary="Cancer.gov" audience="Patient">sinuses</GlossaryTermRef> (hollow areas) around the nose, <GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045203" dictionary="Cancer.gov" audience="Patient">Burkitt lymphoma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000597158" dictionary="Cancer.gov" audience="Patient">lymphoblastic lymphoma</GlossaryTermRef>, and some <GlossaryTermRef href="CDR0000046053" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef> <GlossaryTermRef href="CDR0000045924" dictionary="Cancer.gov" audience="Patient">T-cell lymphomas</GlossaryTermRef>. It is given  to lessen the chance that lymphoma cells will spread to the brain and <GlossaryTermRef href="CDR0000340937" dictionary="Cancer.gov" audience="Patient">spinal cord</GlossaryTermRef>. This is called <GlossaryTermRef href="CDR0000046472" dictionary="Cancer.gov" audience="Patient">CNS prophylaxis</GlossaryTermRef>.</Para><MediaLink ref="CDR0000539773" type="image/jpeg" alt="Intrathecal chemotherapy; drawing shows the cerebrospinal fluid (CSF) in the brain and spinal cord, and an Ommaya reservoir (a dome-shaped container that is placed under the scalp during surgery; it holds the drugs as they flow through a small tube into the brain). Top section shows a syringe and needle injecting anticancer drugs into the Ommaya reservoir. Bottom section shows a syringe and needle injecting anticancer drugs directly into the cerebrospinal fluid in the lower part of the spinal column." language="en" placement="image-center" id="_455"><Caption language="en">Intrathecal chemotherapy. Anticancer drugs are injected into the intrathecal space, which is the space that holds the cerebrospinal fluid (CSF, shown in blue). There are two different ways to do this. One way, shown in the top part of the figure, is to inject the drugs into an Ommaya reservoir (a dome-shaped container that is placed under the scalp during surgery; it holds the drugs as they flow through a small tube into the brain). The other way, shown in the bottom part of the figure, is to inject the drugs directly into the CSF in the lower part of the spinal column, after a small area on the lower back is numbed.  </Caption></MediaLink><Para id="_295">When a pregnant woman is treated with chemotherapy for non-Hodgkin lymphoma, the fetus cannot be protected from being exposed to chemotherapy. Some chemotherapy regimens may cause birth defects if given in the first trimester.</Para><Para id="_324">For more information, see <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef>.</Para></SummarySection><SummarySection id="_457"><KeyPoint id="_460">Immunotherapy</KeyPoint><Para id="_157"><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> is a treatment that uses the patient’s <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> to fight cancer.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.</Para><ItemizedList id="_478" Style="bullet" Compact="No"><ListItem><GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">Immunomodulators</GlossaryTermRef>: <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> is an immunomodulator used to treat non-Hodgkin lymphoma.</ListItem><ListItem>CAR T-cell therapy: The patient's <GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef> (a type of immune system cell) are changed so they will attack certain <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> on the surface of cancer cells. T cells are taken from the patient and special <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> are added to their surface in the laboratory. The changed cells are called <GlossaryTermRef href="CDR0000787969" dictionary="Cancer.gov" audience="Patient">chimeric antigen receptor</GlossaryTermRef> (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. The CAR T cells multiply in the patient's <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> and attack cancer cells. CAR T-cell therapy (such as <GlossaryTermRef href="CDR0000791266" dictionary="Cancer.gov" audience="Patient">axicabtagene ciloleucel</GlossaryTermRef> or  <GlossaryTermRef href="CDR0000790747" dictionary="Cancer.gov" audience="Patient">tisagenlecleucel</GlossaryTermRef>) is used to  treat large <GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma</GlossaryTermRef> that has not <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">responded</GlossaryTermRef> to treatment. CAR T-cell therapy is being studied  to treat    <GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">mantle cell lymphoma</GlossaryTermRef> that has <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or not responded to treatment.</ListItem></ItemizedList><MediaLink ref="CDR0000774647" type="image/jpeg" alt="CAR T-cell therapy; drawing of blood being removed from a vein in a patient’s arm to get T cells. Also shown is a special receptor called a chimeric antigen receptor (CAR) being made in the laboratory; the gene for CAR is inserted into the T cells and then millions of CAR T cells are grown. Drawing also shows the CAR T cells being given to the patient by infusion and binding to antigens on the cancer cells and killing them." language="en" placement="image-center" id="_467"><Caption language="en">CAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them.</Caption></MediaLink><Para id="_461">For more information, see <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef>.</Para></SummarySection><SummarySection id="_208"><KeyPoint id="_265">Targeted therapy</KeyPoint><Para id="_318">Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.  <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal
				antibody</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>, <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef> therapy, and <GlossaryTermRef href="CDR0000750798" dictionary="Cancer.gov" audience="Patient">kinase inhibitor</GlossaryTermRef> therapy are types of targeted therapy used to treat non-Hodgkin lymphoma.</Para><ItemizedList id="_510" Style="bullet"><ListItem>Monoclonal
				antibody therapy: Monoclonal antibodies are <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> proteins made in the laboratory to treat many diseases, including cancer.  As a cancer treatment, these <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> can attach to a specific target on cancer cells or other cells that may help cancer cells grow.  The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading.  Monoclonal antibodies are given by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>.  They may be used alone or to carry drugs, <GlossaryTermRef href="CDR0000046622" dictionary="Cancer.gov" audience="Patient">toxins</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> material directly to cancer cells.  <Para id="_511">Types of monoclonal antibodies include:</Para><ItemizedList id="_512" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">Rituximab</GlossaryTermRef>, used to treat many types of non-Hodgkin lymphoma. </ListItem><ListItem><GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">Obinutuzumab</GlossaryTermRef>, used to treat <GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular lymphoma</GlossaryTermRef>. </ListItem><ListItem><GlossaryTermRef href="CDR0000794274" dictionary="Cancer.gov" audience="Patient">Mogamulizumab</GlossaryTermRef>, used to treat certain types of <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000045924" dictionary="Cancer.gov" audience="Patient">T-cell lymphoma</GlossaryTermRef>.  </ListItem><ListItem><GlossaryTermRef href="CDR0000802193" dictionary="Cancer.gov" audience="Patient">Tafasitamab</GlossaryTermRef> combined with  lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma.</ListItem><ListItem><GlossaryTermRef href="CDR0000764538" dictionary="Cancer.gov" audience="Patient">Pembrolizumab</GlossaryTermRef> to treat <GlossaryTermRef href="CDR0000777025" dictionary="Cancer.gov" audience="Patient">primary mediastinal large B-cell lymphoma</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000798457" dictionary="Cancer.gov" audience="Patient">Polatuzumab vedotin</GlossaryTermRef>, combined with <GlossaryTermRef href="CDR0000386197" dictionary="Cancer.gov" audience="Patient">bendamustine</GlossaryTermRef> and rituximab to treat relapsed or refractory <GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000710543" dictionary="Cancer.gov" audience="Patient">Brentuximab vedotin</GlossaryTermRef>, which contains a monoclonal antibody that binds to a protein called <GlossaryTermRef href="CDR0000796822" dictionary="Cancer.gov" audience="Patient">CD30</GlossaryTermRef> that is found on some lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.</ListItem><ListItem><GlossaryTermRef href="CDR0000046020" dictionary="Cancer.gov" audience="Patient">Yttrium Y 90-ibritumomab tiuxetan</GlossaryTermRef>,  an example of a <GlossaryTermRef href="CDR0000045857" dictionary="Cancer.gov" audience="Patient">radiolabeled</GlossaryTermRef> monoclonal antibody.</ListItem><ListItem><GlossaryTermRef href="CDR0000811230" dictionary="Cancer.gov" audience="Patient">Mosunetuzumab</GlossaryTermRef>, which is a <GlossaryTermRef href="CDR0000044582" dictionary="Cancer.gov" audience="Patient">bispecific monoclonal antibody</GlossaryTermRef> that helps the body's immune system recognize and kill cancer cells. It is used to treat relapsed or refractory follicular lymphoma.</ListItem></ItemizedList><EmbeddedVideo id="_515" ref="CDR0000801837" hosting="youtube" unique_id="dxnjAc-rqz8" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>monoclonal antibodies: how monoclonal antibodies treat cancer</VideoTitle><Caption language="en">How do  monoclonal antibodies work to treat cancer? This video shows how monoclonal antibodies, such as trastuzumab, pembrolizumab, and rituximab, block molecules cancer cells need to grow, flag cancer cells for destruction by the body’s immune system, or deliver harmful substances to cancer cells. </Caption></EmbeddedVideo></ListItem><ListItem>Proteasome inhibitor therapy: This treatment blocks the action of proteasomes in cancer cells. Proteasomes remove <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> no longer needed by the cell. When the proteasomes are blocked, the proteins build up in the cell and may cause the cancer cell to die. <GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">Bortezomib</GlossaryTermRef> or <GlossaryTermRef href="CDR0000777065" dictionary="Cancer.gov" audience="Patient">ixazomib</GlossaryTermRef> is used to decrease how much <GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> M is in the blood after cancer treatment for <GlossaryTermRef href="CDR0000409750" dictionary="Cancer.gov" audience="Patient">lymphoplasmacytic lymphoma</GlossaryTermRef> (Waldenström macroglobulinemia). It is also being studied to treat <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> <GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">mantle cell lymphoma</GlossaryTermRef>.</ListItem><ListItem>Kinase inhibitor therapy: This treatment  blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:<ItemizedList id="_513" Style="bullet"> <ListItem><GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">Ibrutinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000791334" dictionary="Cancer.gov" audience="Patient">acalabrutinib</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000799967" dictionary="Cancer.gov" audience="Patient">zanubrutinib</GlossaryTermRef>, which are types of Bruton <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> therapy. They are used to treat mantle cell lymphoma. Ibrutinib and acalabrutinib are also used to treat lymphoplasmacytic lymphoma, and zanubrutinib is being studied to treat it. </ListItem></ItemizedList></ListItem><ListItem><GlossaryTermRef href="CDR0000784255" dictionary="Cancer.gov" audience="Patient">Histone methyltransferase inhibitor</GlossaryTermRef> therapy: <GlossaryTermRef href="CDR0000793179" dictionary="Cancer.gov" audience="Patient">Tazemetostat</GlossaryTermRef> is used to treat follicular lymphoma that has come back or has not gotten better with other treatment. It is used in adults whose cancer has a certain <GlossaryTermRef href="CDR0000046063" dictionary="Cancer.gov" audience="Patient">mutation</GlossaryTermRef> (change) in the <GlossaryTermRef href="CDR0000801889" dictionary="Cancer.gov" audience="Patient">EZH2 gene</GlossaryTermRef> that has already been treated with at least two other anticancer therapies.  </ListItem><ListItem><GlossaryTermRef href="CDR0000613899" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma-2</GlossaryTermRef> (BCL-2) inhibitor therapy: <GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">Venetoclax</GlossaryTermRef> may be used to treat mantle cell lymphoma. It blocks the action of a protein called  BCL-2 and  may help kill cancer cells.</ListItem></ItemizedList><Para id="_325">For more information, see <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef>.</Para></SummarySection><SummarySection id="_343"><KeyPoint id="_344">Plasmapheresis</KeyPoint><Para id="_345">If the blood becomes thick with extra antibody proteins and affects <GlossaryTermRef href="CDR0000476484" dictionary="Cancer.gov" audience="Patient">circulation</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045483" dictionary="Cancer.gov" audience="Patient">plasmapheresis</GlossaryTermRef> is done to remove extra <GlossaryTermRef href="CDR0000045839" dictionary="Cancer.gov" audience="Patient">plasma</GlossaryTermRef> and antibody proteins from the blood. In this procedure, blood is removed from the patient and sent through a  machine that separates the plasma (the liquid part of the blood) from the blood cells. The patient's plasma contains the unneeded antibodies and is not returned to the patient. The normal blood cells are returned to the bloodstream along with <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donated</GlossaryTermRef> plasma or a plasma  replacement. Plasmapheresis does not keep new antibodies from forming. </Para></SummarySection><SummarySection id="_203"><KeyPoint id="_204">Watchful waiting
			 </KeyPoint><Para id="_205"><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> is
			 closely <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitoring</GlossaryTermRef> a patient’s <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef> without giving any treatment until
			 signs or symptoms appear or change. </Para></SummarySection><SummarySection id="_366"><KeyPoint id="_367">Antibiotic therapy</KeyPoint><Para id="_368"><GlossaryTermRef href="CDR0000045967" dictionary="Cancer.gov" audience="Patient">Antibiotic</GlossaryTermRef> therapy is a treatment that uses drugs to treat <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infections</GlossaryTermRef> and cancer caused by <GlossaryTermRef href="CDR0000044123" dictionary="Cancer.gov" audience="Patient">bacteria</GlossaryTermRef> and other <GlossaryTermRef href="CDR0000044059" dictionary="Cancer.gov" audience="Patient">microorganisms</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_369"><KeyPoint id="_370">Surgery</KeyPoint><Para id="_371"><GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">Surgery</GlossaryTermRef> may be used to remove the lymphoma in certain patients with <GlossaryTermRef href="CDR0000045735" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef> non-Hodgkin lymphoma.</Para><Para id="_374">The type of surgery used depends on where the lymphoma formed in the body:</Para><ItemizedList id="_375" Style="bullet"><ListItem>Local <GlossaryTermRef href="CDR0000269459" dictionary="Cancer.gov" audience="Patient">excision</GlossaryTermRef> for certain patients with <GlossaryTermRef href="CDR0000044437" dictionary="Cancer.gov" audience="Patient">mucosa-associated lymphoid tissue (MALT) lymphoma</GlossaryTermRef>, PTLD, and small bowel T-cell lymphoma.</ListItem><ListItem><GlossaryTermRef href="CDR0000046594" dictionary="Cancer.gov" audience="Patient">Splenectomy</GlossaryTermRef> for patients with <GlossaryTermRef href="CDR0000543124" dictionary="Cancer.gov" audience="Patient">marginal zone lymphoma</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_372">Patients who have a heart, <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046325" dictionary="Cancer.gov" audience="Patient">kidney</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">pancreas</GlossaryTermRef> <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplant</GlossaryTermRef> usually need to take drugs to suppress their immune system for the rest of their lives. Long-term <GlossaryTermRef href="CDR0000045727" dictionary="Cancer.gov" audience="Patient">immunosuppression</GlossaryTermRef> after an organ transplant can cause a certain type of non-Hodgkin lymphoma called <GlossaryTermRef href="CDR0000468786" dictionary="Cancer.gov" audience="Patient">posttransplant lymphoproliferative disorder</GlossaryTermRef> (PLTD).</Para><Para id="_373">Small <GlossaryTermRef href="CDR0000046500" dictionary="Cancer.gov" audience="Patient">bowel</GlossaryTermRef> surgery is often needed to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> <GlossaryTermRef href="CDR0000377726" dictionary="Cancer.gov" audience="Patient">celiac disease</GlossaryTermRef> in adults who develop a type of T-cell lymphoma.</Para></SummarySection><SummarySection id="_213"><KeyPoint id="_214">Stem cell transplant</KeyPoint><Para id="_215">Stem cell transplant is a method of giving high <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of chemotherapy and/or total-body irradiation and then replacing blood-forming cells destroyed by the cancer treatment.  <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> of the patient (<GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous transplant</GlossaryTermRef>) or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000270732" dictionary="Cancer.gov" audience="Patient">allogeneic transplant</GlossaryTermRef>) and are frozen and stored.  After the chemotherapy and/or radiation therapy is completed, the stored stem cells are thawed and given back to the patient through an infusion.  These reinfused stem cells grow into (and restore) the body’s blood cells.</Para><MediaLink ref="CDR0000765030" type="image/jpeg" alt="Donor stem cell transplant; (Panel 1): Drawing of stem cells being collected from a donor's bloodstream using an apheresis machine. Blood is removed from a vein in the donor's arm and flows through the machine where the stem cells are removed. The rest of the blood is then returned to the donor through a vein in their other arm. (Panel 2): Drawing of a health care provider giving a patient an infusion of chemotherapy through a catheter in the patient's chest. The chemotherapy is given to kill cancer cells and prepare the patient's body for the donor stem cells. (Panel 3): Drawing of a patient receiving an infusion of the donor stem cells through a catheter in the chest." language="en" placement="image-center" id="_456"><Caption language="en">Donor stem cell transplant. (Step 1): Four to five days before donor stem cell collection, the donor receives a medicine to increase the number of stem cells circulating through their bloodstream (not shown). The blood-forming stem cells are then collected from the donor through a large vein in their arm. The blood flows through an apheresis machine that removes the stem cells. The rest of the blood is returned to the donor through a vein in their other arm. (Step 2): The patient receives chemotherapy to kill cancer cells and prepare their body for the donor stem cells. The patient may also receive radiation therapy (not shown). (Step 3): The patient receives an infusion of the donor stem cells.</Caption></MediaLink></SummarySection></SummarySection><SummarySection id="_206"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_207">New types of treatment are being tested in clinical
		  trials.</KeyPoint><Para id="_301">This summary section describes treatments that are being studied in
		  clinical trials. It may not mention every new treatment being studied.
		  Information about clinical trials is available from the
		  <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><SummarySection id="_268"><KeyPoint id="_269">Vaccine therapy</KeyPoint><Para id="_270"><GlossaryTermRef href="CDR0000386223" dictionary="Cancer.gov" audience="Patient">Vaccine therapy</GlossaryTermRef> is a cancer treatment that uses a substance or group of substances to stimulate the immune system to find the <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> and kill it.</Para></SummarySection></SummarySection><SummarySection id="_304"><KeyPoint id="_305">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_304_md_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard treatment</GlossaryTermRef>.</Para><Para id="_304_md_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_304_md_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_306"><KeyPoint id="_307">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_306_md_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_306_md_30">Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trials search</ExternalRef> webpage. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para></SummarySection><SummarySection id="_308"><KeyPoint id="_309">Follow-up tests may be needed.</KeyPoint><Para id="_308_md_33">As you go through treatment, you  will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_308_md_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_419"><Title>Treatment of Indolent Non-Hodgkin Lymphoma</Title><Para id="_469">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_420">Treatment of <GlossaryTermRef href="CDR0000046355" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef>
		  <GlossaryTermRef href="CDR0000045906" dictionary="Cancer.gov" audience="Patient">stage I</GlossaryTermRef> and indolent, <GlossaryTermRef href="CDR0000350356" dictionary="Cancer.gov" audience="Patient">contiguous</GlossaryTermRef>
		  <GlossaryTermRef href="CDR0000045907" dictionary="Cancer.gov" audience="Patient">stage II</GlossaryTermRef>
		  <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> may include
		  the following:</Para><ItemizedList id="_421" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibody</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>) and/or <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_422">If the <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef> is too large to be treated with radiation therapy, the treatment options for indolent, <GlossaryTermRef href="CDR0000350357" dictionary="Cancer.gov" audience="Patient">noncontiguous</GlossaryTermRef> <GlossaryTermRef href="CDR0000045907" dictionary="Cancer.gov" audience="Patient">stage II</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045908" dictionary="Cancer.gov" audience="Patient">III</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045909" dictionary="Cancer.gov" audience="Patient">IV</GlossaryTermRef>
		  non-Hodgkin lymphoma will be used.</Para><Para id="_425">Treatment of indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:</Para><ItemizedList id="_426" Style="bullet"><ListItem>Watchful waiting for patients who do not have <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or
			 <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>.</ListItem> 
		  <ListItem>Monoclonal
			 antibody therapy (rituximab) with or without chemotherapy.</ListItem><ListItem><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> and rituximab.</ListItem><ListItem><GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">Maintenance therapy</GlossaryTermRef> with rituximab.</ListItem><ListItem>Monoclonal antibody therapy (<GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">obinutuzumab</GlossaryTermRef>) with or without chemotherapy.</ListItem> 
		   
		  <ListItem><GlossaryTermRef href="CDR0000801889" dictionary="Cancer.gov" audience="Patient">EZH2</GlossaryTermRef> inhibitor therapy (<GlossaryTermRef href="CDR0000793179" dictionary="Cancer.gov" audience="Patient">tazemetostat</GlossaryTermRef>).</ListItem> <ListItem><GlossaryTermRef href="CDR0000045857" dictionary="Cancer.gov" audience="Patient">Radiolabeled</GlossaryTermRef> monoclonal antibody
			 therapy.</ListItem> 
		  <ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000346522" dictionary="Cancer.gov" audience="Patient">high-dose chemotherapy</GlossaryTermRef> with or without
			 <GlossaryTermRef href="CDR0000045930" dictionary="Cancer.gov" audience="Patient">total-body irradiation</GlossaryTermRef> or radiolabeled monoclonal antibody therapy, followed by <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous</GlossaryTermRef> or <GlossaryTermRef href="CDR0000270732" dictionary="Cancer.gov" audience="Patient">allogeneic  stem cell transplant</GlossaryTermRef>.</ListItem> 
		  <ListItem>A clinical trial of chemotherapy with or without
			 <GlossaryTermRef href="CDR0000386223" dictionary="Cancer.gov" audience="Patient">vaccine therapy</GlossaryTermRef>.</ListItem><ListItem>A clinical trial of new types of monoclonal antibodies.</ListItem> 
		<ListItem> A clinical trial of radiation therapy that includes nearby <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, for patients who have stage III disease.</ListItem><ListItem>A clinical trial of <GlossaryTermRef href="CDR0000792092" dictionary="Cancer.gov" audience="Patient">low-dose radiation therapy</GlossaryTermRef>, to relieve symptoms and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_423">Other treatments for indolent non-Hodgkin lymphoma depend on the type of non-Hodgkin lymphoma. Treatment may include the following:</Para><ItemizedList id="_424" Style="bullet"><ListItem>For <GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular lymphoma</GlossaryTermRef>, treatment may be within a clinical trial of new monoclonal antibody therapy, new chemotherapy <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimen</GlossaryTermRef>, or a <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</ListItem><ListItem>For <GlossaryTermRef href="CDR0000409750" dictionary="Cancer.gov" audience="Patient">lymphoplasmacytic lymphoma</GlossaryTermRef> (Waldenström macroglobulinemia), <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> therapy  and/or <GlossaryTermRef href="CDR0000045483" dictionary="Cancer.gov" audience="Patient">plasmapheresis</GlossaryTermRef>  or <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef> therapy (if needed to make the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> thinner) is used. Other treatments that are like those used for follicular lymphoma may also be given.</ListItem><ListItem>For <GlossaryTermRef href="CDR0000046770" dictionary="Cancer.gov" audience="Patient">gastric</GlossaryTermRef> <GlossaryTermRef href="CDR0000044437" dictionary="Cancer.gov" audience="Patient">mucosa-associated lymphoid tissue (MALT) lymphoma</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045967" dictionary="Cancer.gov" audience="Patient">antibiotic</GlossaryTermRef> therapy to treat <ScientificName><GlossaryTermRef href="CDR0000045706" dictionary="Cancer.gov" audience="Patient">Helicobacter pylori</GlossaryTermRef></ScientificName> <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> is given first. For tumors that do not <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">respond</GlossaryTermRef> to antibiotic therapy, treatment is radiation therapy, <GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgery</GlossaryTermRef>, or rituximab with or without chemotherapy. </ListItem><ListItem>For extragastric MALT lymphoma of the eye and Mediterranean <GlossaryTermRef href="CDR0000046684" dictionary="Cancer.gov" audience="Patient">abdominal</GlossaryTermRef> <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>, antibiotic therapy is used to treat infection.</ListItem><ListItem>For <GlossaryTermRef href="CDR0000467863" dictionary="Cancer.gov" audience="Patient">splenic</GlossaryTermRef> <GlossaryTermRef href="CDR0000543124" dictionary="Cancer.gov" audience="Patient">marginal zone lymphoma</GlossaryTermRef>, rituximab with or without chemotherapy and B-cell receptor therapy is used as initial treatment. If the tumor does not respond to treatment, a <GlossaryTermRef href="CDR0000046594" dictionary="Cancer.gov" audience="Patient">splenectomy</GlossaryTermRef> may be done.</ListItem></ItemizedList></SummarySection><SummarySection id="_428"><Title>Treatment of Aggressive Non-Hodgkin Lymphoma</Title><Para id="_470">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_429">Treatment of <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef>  <GlossaryTermRef href="CDR0000045906" dictionary="Cancer.gov" audience="Patient">stage I</GlossaryTermRef> and aggressive, <GlossaryTermRef href="CDR0000350356" dictionary="Cancer.gov" audience="Patient">contiguous</GlossaryTermRef> <GlossaryTermRef href="CDR0000045907" dictionary="Cancer.gov" audience="Patient">stage II</GlossaryTermRef>  <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> may include the following:</Para><ItemizedList id="_430" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibody</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>) and <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef>. Sometimes <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> is given later.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of a new <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimen</GlossaryTermRef> of monoclonal antibody therapy and combination chemotherapy.</ListItem></ItemizedList><Para id="_431">Treatment of aggressive, <GlossaryTermRef href="CDR0000350357" dictionary="Cancer.gov" audience="Patient">noncontiguous</GlossaryTermRef> <GlossaryTermRef href="CDR0000045907" dictionary="Cancer.gov" audience="Patient">stage II</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045908" dictionary="Cancer.gov" audience="Patient">III</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045909" dictionary="Cancer.gov" audience="Patient">IV</GlossaryTermRef> non-Hodgkin lymphoma may include the following:</Para><ItemizedList id="_432" Style="bullet"><ListItem>Monoclonal antibody therapy (rituximab) with combination chemotherapy.</ListItem><ListItem>Combination chemotherapy.</ListItem> 
		   
		   
		<ListItem>A clinical trial of monoclonal antibody therapy with combination chemotherapy followed by radiation therapy.</ListItem></ItemizedList><Para id="_433">Other treatments depend on the type of aggressive non-Hodgkin lymphoma. Treatment may include the following:</Para><ItemizedList id="_434" Style="bullet"><ListItem>For <GlossaryTermRef href="CDR0000539104" dictionary="Cancer.gov" audience="Patient">extranodal</GlossaryTermRef> <GlossaryTermRef href="CDR0000044439" dictionary="Cancer.gov" audience="Patient">NK</GlossaryTermRef>-/<GlossaryTermRef href="CDR0000045924" dictionary="Cancer.gov" audience="Patient">T-cell lymphoma</GlossaryTermRef>, radiation therapy that may be given before, during, or after <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046472" dictionary="Cancer.gov" audience="Patient">CNS prophylaxis</GlossaryTermRef>. </ListItem><ListItem>For <GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">mantle cell lymphoma</GlossaryTermRef>, monoclonal antibody therapy with combination chemotherapy, followed by <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>. Monoclonal antibody therapy may be given afterwards as <GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance therapy</GlossaryTermRef> (treatment that is given after initial therapy to help keep cancer from coming back).</ListItem><ListItem>For <GlossaryTermRef href="CDR0000468786" dictionary="Cancer.gov" audience="Patient">posttransplantation lymphoproliferative disorder</GlossaryTermRef>, treatment with <GlossaryTermRef href="CDR0000044041" dictionary="Cancer.gov" audience="Patient">immunosuppressive</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> may be stopped. If this does not work or cannot be done, monoclonal antibody therapy  alone or with chemotherapy may be given. For <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> that has not spread, <GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgery</GlossaryTermRef> to remove the cancer or radiation therapy may be used.</ListItem><ListItem>For <GlossaryTermRef href="CDR0000776368" dictionary="Cancer.gov" audience="Patient">plasmablastic lymphoma</GlossaryTermRef>, treatments are like those used for <GlossaryTermRef href="CDR0000597158" dictionary="Cancer.gov" audience="Patient">lymphoblastic lymphoma</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045203" dictionary="Cancer.gov" audience="Patient">Burkitt lymphoma</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_435">For information on the treatment of lymphoblastic lymphoma, see <SummaryRef href="CDR0000062958#_436" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Options for Lymphoblastic Lymphoma</SummaryRef> and for information on the treatment of Burkitt lymphoma, see <SummaryRef href="CDR0000062958#_439" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Options for Burkitt Lymphoma</SummaryRef>.</Para></SummarySection><SummarySection id="_436"><Title>Treatment of Lymphoblastic Lymphoma</Title><Para id="_471">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_437">Treatment of <GlossaryTermRef href="CDR0000597158" dictionary="Cancer.gov" audience="Patient">lymphoblastic lymphoma</GlossaryTermRef> may include the
		  following:</Para><ItemizedList id="_438" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046472" dictionary="Cancer.gov" audience="Patient">CNS prophylaxis</GlossaryTermRef>. Sometimes <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> is also given to shrink a large <GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">tumor</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> alone (<GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>) or combined with <GlossaryTermRef href="CDR0000750798" dictionary="Cancer.gov" audience="Patient">kinase inhibitor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">ibrutinib</GlossaryTermRef>).</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef> after initial treatment.</ListItem></ItemizedList></SummarySection><SummarySection id="_439"><Title>Treatment of Burkitt Lymphoma</Title><Para id="_472">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_440">Treatment of <GlossaryTermRef href="CDR0000045203" dictionary="Cancer.gov" audience="Patient">Burkitt lymphoma</GlossaryTermRef>
		  may include the following:</Para><ItemizedList id="_441" Style="bullet"> 
		   
		  <ListItem><GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> with or without <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046472" dictionary="Cancer.gov" audience="Patient">CNS prophylaxis</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_442"><Title>Treatment of Recurrent Non-Hodgkin Lymphoma</Title><Para id="_473">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_443">Treatment of <GlossaryTermRef href="CDR0000046355" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef>,
		<GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> may include
		the following:</Para><ItemizedList id="_444" Style="bullet"> 
		<ListItem><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibody</GlossaryTermRef>
		  <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef> or <GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">obinutuzumab</GlossaryTermRef>) with or without <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> and rituximab.</ListItem><ListItem><GlossaryTermRef href="CDR0000801889" dictionary="Cancer.gov" audience="Patient">EZH2</GlossaryTermRef> inhibitor therapy (<GlossaryTermRef href="CDR0000793179" dictionary="Cancer.gov" audience="Patient">tazemetostat</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative therapy</GlossaryTermRef> to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> with one or more <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045857" dictionary="Cancer.gov" audience="Patient">Radiolabeled</GlossaryTermRef> monoclonal antibody therapy.</ListItem> 
		 
		 
		 
		 
		<ListItem><GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044582" dictionary="Cancer.gov" audience="Patient">Bispecific monoclonal antibody</GlossaryTermRef> therapy (<GlossaryTermRef href="CDR0000811230" dictionary="Cancer.gov" audience="Patient">mosunetuzumab</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_445">Treatment of <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef>,
		recurrent non-Hodgkin lymphoma may include the following:</Para><ItemizedList id="_446" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000791266" dictionary="Cancer.gov" audience="Patient">axicabtagene ciloleucel</GlossaryTermRef> for <GlossaryTermRef href="CDR0000748354" dictionary="Cancer.gov" audience="Patient">primary</GlossaryTermRef> <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> disease or <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapse</GlossaryTermRef> within 1 year.</ListItem><ListItem><GlossaryTermRef href="CDR0000045263" dictionary="Cancer.gov" audience="Patient">Bone marrow transplant</GlossaryTermRef> or stem cell transplant <GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">consolidation therapy</GlossaryTermRef>.</ListItem><ListItem>CAR T-cell therapy for relapse after <GlossaryTermRef href="CDR0000044912" dictionary="Cancer.gov" audience="Patient">autologous</GlossaryTermRef> stem cell transplant.</ListItem><ListItem><GlossaryTermRef href="CDR0000802193" dictionary="Cancer.gov" audience="Patient">Tafasitamab</GlossaryTermRef> plus lenalidomide.</ListItem><ListItem>Rituximab plus lenalidomide.</ListItem><ListItem><GlossaryTermRef href="CDR0000798457" dictionary="Cancer.gov" audience="Patient">Polatuzumab vedotin</GlossaryTermRef> plus rituximab and <GlossaryTermRef href="CDR0000386197" dictionary="Cancer.gov" audience="Patient">bendamustine</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000804892" dictionary="Cancer.gov" audience="Patient">Loncastuximab tesirine</GlossaryTermRef>.</ListItem><ListItem>Bispecific monoclonal antibody therapy (mosunetuzumab).</ListItem><ListItem>Chemotherapy with or without <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</ListItem><ListItem>For certain <GlossaryTermRef href="CDR0000045924" dictionary="Cancer.gov" audience="Patient">T-cell lymphomas</GlossaryTermRef>, monoclonal antibody therapy with      <GlossaryTermRef href="CDR0000794274" dictionary="Cancer.gov" audience="Patient">mogamulizumab</GlossaryTermRef>.</ListItem><ListItem>Monoclonal antibody therapy with or without <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef> followed by autologous stem cell transplant.</ListItem><ListItem>Radiation therapy as
		  palliative therapy to relieve symptoms and improve quality of
		  life.</ListItem><ListItem>Radiolabeled monoclonal antibody therapy.</ListItem><ListItem>For <GlossaryTermRef href="CDR0000445048" dictionary="Cancer.gov" audience="Patient">mantle cell lymphoma</GlossaryTermRef>, treatment may include the following:<ItemizedList id="_459" Style="bullet"><ListItem>Bruton <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> therapy.</ListItem><ListItem>Rituximab with or without a tyrosine kinase inhibitor (<GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">ibrutinib</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef>.</ListItem><ListItem>A clinical trial of lenalidomide  with monoclonal antibody therapy.</ListItem><ListItem>A clinical trial comparing lenalidomide to other therapy.</ListItem><ListItem>A clinical trial of <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef> therapy (<GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">bortezomib</GlossaryTermRef>).</ListItem></ItemizedList></ListItem><ListItem>For <GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef>, treatment may include the following:<ItemizedList id="_514" Style="bullet">
     <ListItem>Tafasitamab plus lenalidomide.</ListItem><ListItem>Polatuzumab vedotin, combined with bendamustine and rituximab.</ListItem></ItemizedList></ListItem><ListItem> A clinical trial of autologous or allogeneic stem cell transplant.</ListItem> 
		</ItemizedList><Para id="_447">Treatment of <GlossaryTermRef href="CDR0000045735" dictionary="Cancer.gov" audience="Patient">indolent
		lymphoma</GlossaryTermRef> that comes back as <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive lymphoma</GlossaryTermRef> depends on the type of non-Hodgkin lymphoma and may include radiation therapy as palliative therapy to relieve symptoms and improve quality of life. Treatment of aggressive lymphoma that comes back as indolent lymphoma may include chemotherapy.</Para></SummarySection><SummarySection id="_354"><Title>Treatment of Non-Hodgkin Lymphoma During Pregnancy</Title><Para id="_474">For information about the treatments listed below, see the <SummaryRef href="CDR0000062958#_195" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><SummarySection id="_357"><Title>Indolent Non-Hodgkin Lymphoma During Pregnancy</Title><Para id="_292"> 
Women who have
		  <GlossaryTermRef href="CDR0000046355" dictionary="Cancer.gov" audience="Patient">indolent</GlossaryTermRef> (slow-growing)
		  <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> during <GlossaryTermRef href="CDR0000666677" dictionary="Cancer.gov" audience="Patient">pregnancy</GlossaryTermRef> may be treated with <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef> until after they give birth. (See the <SummaryRef href="CDR0000062958#_419" url="/types/lymphoma/patient/adult-nhl-treatment-pdq">Treatment Options for Indolent Non-Hodgkin Lymphoma</SummaryRef> section for more information.)</Para></SummarySection><SummarySection id="_358"><Title>Aggressive Non-Hodgkin Lymphoma During Pregnancy</Title><Para id="_359">Treatment of <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef>
		  <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef> during <GlossaryTermRef href="CDR0000666677" dictionary="Cancer.gov" audience="Patient">pregnancy</GlossaryTermRef> may include the following:</Para><ItemizedList id="_360" Style="bullet"><ListItem>Treatment given right away based on the type of non-Hodgkin lymphoma to increase the mother's chance of <GlossaryTermRef href="CDR0000450125" dictionary="Cancer.gov" audience="Patient">survival</GlossaryTermRef>. Treatment may include <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>.</ListItem><ListItem>Early delivery of the baby followed by treatment based on the type of non-Hodgkin lymphoma.</ListItem><ListItem>If in the first trimester of pregnancy, <GlossaryTermRef href="CDR0000046290" dictionary="Cancer.gov" audience="Patient">medical oncologists</GlossaryTermRef> may advise ending the pregnancy so that treatment may begin.   Treatment depends on the type of non-Hodgkin lymphoma.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_271"><Title>To Learn More About Non-Hodgkin Lymphoma</Title><Para id="_272">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef>, see the following: </Para><ItemizedList id="_326" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/types/lymphoma">Non-Hodgkin Lymphoma Home Page</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/non-hodgkin">Drugs Approved for Non-Hodgkin Lymphoma</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">Immunotherapy to Treat Cancer</ExternalRef></ListItem></ItemizedList><Para id="_271_md_40">For general cancer information and other resources from the National Cancer Institute, visit:</Para><ItemizedList id="_271_md_41" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of adult non-Hodgkin lymphoma.  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Adult Treatment Editorial Board. PDQ Non-Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq">https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389337]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2024-08-22</DateLastModified></Summary>
